

WEBVTT

NOTE duration:"01:02:13.170000"

NOTE recognizability:0.835

NOTE language:en-us

NOTE Confidence: 0.86236195

00:00:00.000 --> 00:00:04.315 Welcome everyone to the 2023 Post American

NOTE Confidence: 0.86236195

00:00:04.315 --> 00:00:06.980 Society of Hematology annual meeting

NOTE Confidence: 0.841294297692308

00:00:07.066 --> 00:00:09.895 at CME series. We are starting off the

NOTE Confidence: 0.841294297692308

00:00:09.895 --> 00:00:11.520 series today with multiple myeloma.

NOTE Confidence: 0.84337565

00:00:12.210 --> 00:00:13.678 Our first two presenters

NOTE Confidence: 0.820358457692308

00:00:13.690 --> 00:00:16.497 are Doctor Nofar Barr and Doctor Sabrina

NOTE Confidence: 0.820358457692308

00:00:16.497 --> 00:00:19.370 Browning who will be reviewing abstracts.

NOTE Confidence: 0.820358457692308

00:00:19.370 --> 00:00:21.120 We will then have a question and

NOTE Confidence: 0.820358457692308

00:00:21.120 --> 00:00:22.964 answer period at the end of the

NOTE Confidence: 0.820358457692308

00:00:22.964 --> 00:00:24.239 presentation where we will be

NOTE Confidence: 0.820358457692308

00:00:24.239 --> 00:00:26.255 joined by two other panelists, Dr.

NOTE Confidence: 0.820358457692308

00:00:26.255 --> 00:00:28.380 Ellen Gorshin and Doctor Natalia

NOTE Confidence: 0.820358457692308

00:00:28.380 --> 00:00:30.358 and appraise. If you could please

NOTE Confidence: 0.820358457692308

00:00:30.358 --> 00:00:32.050 put your questions in the Q&A.

NOTE Confidence: 0.820358457692308

00:00:32.050 --> 00:00:33.070 And save them to the end?

NOTE Confidence: 0.820358457692308

00:00:33.070 --> 00:00:35.210 That would be greatly appreciated.

NOTE Confidence: 0.820358457692308

00:00:35.210 --> 00:00:37.530 I will now turn it over to Doctor Barr.

NOTE Confidence: 0.941861452

00:00:41.630 --> 00:00:43.655 Hi everyone, I'm just gonna

NOTE Confidence: 0.941861452

00:00:43.655 --> 00:00:45.680 start sharing my screen here.

NOTE Confidence: 0.86048138

00:00:54.330 --> 00:00:56.826 Alright, it's good to be here.

NOTE Confidence: 0.86048138

00:00:56.830 --> 00:00:57.712 Good afternoon.

NOTE Confidence: 0.86048138

00:00:57.712 --> 00:01:01.240 Today I'm going to be looking at the

NOTE Confidence: 0.86048138

00:01:01.327 --> 00:01:04.292 newly diagnosed myeloma abstracts in

NOTE Confidence: 0.86048138

00:01:04.292 --> 00:01:06.835 Ashes 2022 this past December with

NOTE Confidence: 0.86048138

00:01:06.835 --> 00:01:08.780 a particular focus on subgroups.

NOTE Confidence: 0.9029528

00:01:13.830 --> 00:01:16.550 So I have no disclosures.

NOTE Confidence: 0.9029528

00:01:16.550 --> 00:01:18.468 The first subgroup I'm going to be

NOTE Confidence: 0.9029528

00:01:18.468 --> 00:01:20.125 speaking about are the frail patients

NOTE Confidence: 0.9029528

00:01:20.125 --> 00:01:21.938 and why is it important to have

NOTE Confidence: 0.9029528

00:01:21.990 --> 00:01:23.886 dedicated studies for these folks is

NOTE Confidence: 0.9029528

00:01:23.886 --> 00:01:25.578 that they have different outcomes,

NOTE Confidence: 0.9029528

00:01:25.578 --> 00:01:27.290 they have shorter survival,

NOTE Confidence: 0.9029528

00:01:27.290 --> 00:01:29.438 they have higher rates of toxicity

NOTE Confidence: 0.9029528

00:01:29.438 --> 00:01:31.369 and therefore higher rates of

NOTE Confidence: 0.9029528

00:01:31.369 --> 00:01:32.689 discontinuation of therapy.

NOTE Confidence: 0.9029528

00:01:32.690 --> 00:01:33.262 Traditionally,

NOTE Confidence: 0.9029528

00:01:33.262 --> 00:01:35.550 studies have categorized myeloma

NOTE Confidence: 0.9029528

00:01:35.550 --> 00:01:38.410 patients as either transplant or

NOTE Confidence: 0.9029528

00:01:38.487 --> 00:01:40.417 transplant ineligible patients,

NOTE Confidence: 0.9029528

00:01:40.417 --> 00:01:42.979 but this category really does not

NOTE Confidence: 0.9029528

00:01:42.979 --> 00:01:45.474 capture frail patients because the frail

NOTE Confidence: 0.9029528

00:01:45.474 --> 00:01:47.766 scores are not routinely checked in

NOTE Confidence: 0.9029528

00:01:47.766 --> 00:01:50.349 those non transplant eligible patients.

NOTE Confidence: 0.9029528

00:01:50.350 --> 00:01:52.838 For a long time the standard of care

NOTE Confidence: 0.9029528

00:01:52.838 --> 00:01:55.138 for non transplant eligible patients
NOTE Confidence: 0.9029528

00:01:55.138 --> 00:01:58.342 was with REVLIMID and dexamethasone Rd.
NOTE Confidence: 0.9029528

00:01:58.350 --> 00:02:00.750 But since the Maya study,
NOTE Confidence: 0.9029528

00:02:00.750 --> 00:02:03.126 we now have a new standard of care
NOTE Confidence: 0.9029528

00:02:03.126 --> 00:02:05.690 for patients which is Derek Tuma Mab
NOTE Confidence: 0.9029528

00:02:05.690 --> 00:02:07.590 REVLIMID and dexamethasone there Rd.
NOTE Confidence: 0.9029528

00:02:07.590 --> 00:02:12.950 So what the FM 2017 O3 study analyzed
NOTE Confidence: 0.9029528

00:02:12.950 --> 00:02:15.950 is removal of dexamethasone early.
NOTE Confidence: 0.9029528

00:02:15.950 --> 00:02:18.476 So they hypothesized if you take
NOTE Confidence: 0.9029528

00:02:18.476 --> 00:02:20.160 away dexamethasone from there.
NOTE Confidence: 0.9029528

00:02:20.160 --> 00:02:20.566 Rd.
NOTE Confidence: 0.9029528

00:02:20.566 --> 00:02:22.596 this will still be effective
NOTE Confidence: 0.9029528

00:02:22.596 --> 00:02:25.180 and it will reduce toxicities.
NOTE Confidence: 0.9029528

00:02:25.180 --> 00:02:26.916 Before we get into the study design,
NOTE Confidence: 0.9029528

00:02:26.920 --> 00:02:29.080 I want to talk about what is a frailty score.
NOTE Confidence: 0.9029528

00:02:29.080 --> 00:02:31.105 Some of you might not have had a chance

NOTE Confidence: 0.9029528

00:02:31.105 --> 00:02:33.256 to take a look at this in your clinic,

NOTE Confidence: 0.9029528

00:02:33.260 --> 00:02:34.876 so I am WG.

NOTE Confidence: 0.9029528

00:02:34.876 --> 00:02:37.300 Frailty score involves a few things.

NOTE Confidence: 0.9029528

00:02:37.300 --> 00:02:39.700 Age, activity of daily living,

NOTE Confidence: 0.9029528

00:02:39.700 --> 00:02:41.764 which involves feeding oneself,

NOTE Confidence: 0.9029528

00:02:41.764 --> 00:02:43.676 bathing oneself, instrumental activities

NOTE Confidence: 0.9029528

00:02:43.676 --> 00:02:46.304 of daily living which involve food,

NOTE Confidence: 0.9029528

00:02:46.310 --> 00:02:48.282 shopping, cleaning the house,

NOTE Confidence: 0.9029528

00:02:48.282 --> 00:02:51.240 doing your finances and the comorbidity

NOTE Confidence: 0.9029528

00:02:51.311 --> 00:02:53.000 index, which is what it means.

NOTE Confidence: 0.9029528

00:02:53.000 --> 00:02:55.070 Comorbidity is like lung disease.

NOTE Confidence: 0.9029528

00:02:55.070 --> 00:02:58.190 Diabetes, liver disease and so forth.

NOTE Confidence: 0.9029528

00:02:58.190 --> 00:02:59.840 Now, as you can imagine,

NOTE Confidence: 0.9029528

00:02:59.840 --> 00:03:01.808 this takes time to do this frailty score.

NOTE Confidence: 0.9029528

00:03:01.810 --> 00:03:03.364 There was a lot of questions involved.

NOTE Confidence: 0.9029528

00:03:03.370 --> 00:03:06.534 So the IM group devised a simplified
NOTE Confidence: 0.9029528

00:03:06.534 --> 00:03:08.290 score which involves age,
NOTE Confidence: 0.9029528

00:03:08.290 --> 00:03:09.750 which is fairly easy,
NOTE Confidence: 0.9029528

00:03:09.750 --> 00:03:10.845 ECOG performance status,
NOTE Confidence: 0.9029528

00:03:10.850 --> 00:03:12.118 which we do routinely,
NOTE Confidence: 0.9029528

00:03:12.118 --> 00:03:13.703 and then the comorbidity index,
NOTE Confidence: 0.9029528

00:03:13.710 --> 00:03:16.447 which is easily accessible from chart review.
NOTE Confidence: 0.9029528

00:03:16.450 --> 00:03:19.030 And if you had a score of two or more,
NOTE Confidence: 0.9029528

00:03:19.030 --> 00:03:20.982 you're classified as frail
NOTE Confidence: 0.9029528

00:03:20.982 --> 00:03:22.934 and otherwise you're fit.
NOTE Confidence: 0.9029528

00:03:22.940 --> 00:03:24.968 So this is the study design.
NOTE Confidence: 0.9029528

00:03:24.970 --> 00:03:26.955 They include a newly diagnosed
NOTE Confidence: 0.9029528

00:03:26.955 --> 00:03:29.830 patients over 65 years of age and I
NOTE Confidence: 0.9029528

00:03:29.830 --> 00:03:32.429 am I FM frailty score of two or above.
NOTE Confidence: 0.9029528

00:03:32.430 --> 00:03:36.136 It was a 2 to one randomization with
NOTE Confidence: 0.9029528

00:03:36.136 --> 00:03:39.666 REVLIMID decks or Dara REVLIMID.

NOTE Confidence: 0.9029528

00:03:39.670 --> 00:03:41.956 I do want to note that with the Dara

NOTE Confidence: 0.9029528

00:03:41.960 --> 00:03:44.368 Revlimid's group which ARM B right here,

NOTE Confidence: 0.9029528

00:03:44.370 --> 00:03:47.016 they did receive steroids for the first

NOTE Confidence: 0.9029528

00:03:47.016 --> 00:03:49.320 two cycles along with dexamethasone

NOTE Confidence: 0.9029528

00:03:49.320 --> 00:03:52.070 primarily to avoid infusion reactions.

NOTE Confidence: 0.9029528

00:03:52.070 --> 00:03:55.250 So their primary endpoint was PFS,

NOTE Confidence: 0.9029528

00:03:55.250 --> 00:03:57.469 but this is immature at the moment.

NOTE Confidence: 0.9029528

00:03:57.470 --> 00:03:59.857 So they did an interim analysis and

NOTE Confidence: 0.9029528

00:03:59.857 --> 00:04:02.289 they looked at response rate including

NOTE Confidence: 0.9029528

00:04:02.289 --> 00:04:04.509 MRD negative rate and occurrence

NOTE Confidence: 0.9029528

00:04:04.509 --> 00:04:07.178 of grade three or more toxicities.

NOTE Confidence: 0.9029528

00:04:07.180 --> 00:04:09.070 I want to highlight here some

NOTE Confidence: 0.9029528

00:04:09.070 --> 00:04:10.330 of the patient characteristics.

NOTE Confidence: 0.9029528

00:04:10.330 --> 00:04:12.594 So if you look at the median age,

NOTE Confidence: 0.9029528

00:04:12.600 --> 00:04:14.544 they were significantly older,

NOTE Confidence: 0.9029528

00:04:14.544 --> 00:04:17.460 median age of 81 compared to
NOTE Confidence: 0.9029528

00:04:17.543 --> 00:04:20.990 the Maya study which was 73.
NOTE Confidence: 0.9029528

00:04:20.990 --> 00:04:22.675 While the inclusion criteria in
NOTE Confidence: 0.9029528

00:04:22.675 --> 00:04:25.013 the study included two or for the
NOTE Confidence: 0.9029528

00:04:25.013 --> 00:04:26.783 frailty score was two or higher,
NOTE Confidence: 0.9029528

00:04:26.790 --> 00:04:28.875 actually the majority of the
NOTE Confidence: 0.9029528

00:04:28.875 --> 00:04:30.960 patients were three and higher.
NOTE Confidence: 0.93684912

00:04:30.960 --> 00:04:33.025 If you look at the risk categories,
NOTE Confidence: 0.93684912

00:04:33.030 --> 00:04:37.310 they were fairly similar in the two groups.
NOTE Confidence: 0.93684912

00:04:37.310 --> 00:04:39.536 So Dara REVLIMID clearly led to
NOTE Confidence: 0.93684912

00:04:39.536 --> 00:04:41.464 deeper response rates than REVLIMID
NOTE Confidence: 0.93684912

00:04:41.464 --> 00:04:43.726 dexamethasone you can see here first
NOTE Confidence: 0.93684912

00:04:43.726 --> 00:04:46.400 based on just the the response rates,
NOTE Confidence: 0.93684912

00:04:46.400 --> 00:04:49.096 you had higher CR and very good partial
NOTE Confidence: 0.93684912

00:04:49.096 --> 00:04:51.598 response rates and then Dara Rev Group and
NOTE Confidence: 0.93684912

00:04:51.598 --> 00:04:54.030 you also had higher MRD negative rates,

NOTE Confidence: 0.93684912

00:04:54.030 --> 00:04:56.890 attentive negative 5th using next

NOTE Confidence: 0.93684912

00:04:56.890 --> 00:05:00.330 generation sequencing 10 compared to three.

NOTE Confidence: 0.93684912

00:05:00.330 --> 00:05:03.147 MRD was assessed at one year in patients who

NOTE Confidence: 0.93684912

00:05:03.147 --> 00:05:06.067 had a very good posture response or higher,

NOTE Confidence: 0.93684912

00:05:06.070 --> 00:05:07.426 it is important to note that.

NOTE Confidence: 0.93684912

00:05:07.430 --> 00:05:10.944 Any missing data was considered MRD positive.

NOTE Confidence: 0.93684912

00:05:10.950 --> 00:05:13.064 So it's important because there is a

NOTE Confidence: 0.93684912

00:05:13.064 --> 00:05:14.979 significant group of patients that have

NOTE Confidence: 0.93684912

00:05:14.979 --> 00:05:17.306 missing data and for example, the Dr.

NOTE Confidence: 0.93684912

00:05:17.306 --> 00:05:20.670 Group had 20% missing data and the Rd.

NOTE Confidence: 0.93684912

00:05:20.670 --> 00:05:22.126 had 14% missing data.

NOTE Confidence: 0.93684912

00:05:22.126 --> 00:05:24.310 And I'm not about to compare

NOTE Confidence: 0.93684912

00:05:24.392 --> 00:05:26.797 different studies to one another,

NOTE Confidence: 0.93684912

00:05:26.800 --> 00:05:28.520 but I want to give us a framework

NOTE Confidence: 0.93684912

00:05:28.520 --> 00:05:30.168 of what the Maya study showed.

NOTE Confidence: 0.93684912

00:05:30.170 --> 00:05:32.994 So in the Maya study they assess MRD
NOTE Confidence: 0.93684912

00:05:32.994 --> 00:05:34.878 negativity, attend to negative 5th,
NOTE Confidence: 0.93684912

00:05:34.878 --> 00:05:37.170 but they used a different assay
NOTE Confidence: 0.93684912

00:05:37.247 --> 00:05:38.427 so they use flow.
NOTE Confidence: 0.93684912

00:05:38.430 --> 00:05:42.066 So flow tends to have a higher MRD negative
NOTE Confidence: 0.93684912

00:05:42.066 --> 00:05:45.338 rate just by the nature of its assets.
NOTE Confidence: 0.93684912

00:05:45.340 --> 00:05:46.690 So just something to note,
NOTE Confidence: 0.93684912

00:05:46.690 --> 00:05:49.946 but they had in the DRD group 24%
NOTE Confidence: 0.93684912

00:05:49.946 --> 00:05:52.578 MRD negativity versus 7 in the Rd.
NOTE Confidence: 0.93684912

00:05:52.580 --> 00:05:56.710 group. In terms of toxicity,
NOTE Confidence: 0.93684912

00:05:56.710 --> 00:05:58.146 which is very important,
NOTE Confidence: 0.93684912

00:05:58.146 --> 00:06:00.970 you can see that Grade 3 or above
NOTE Confidence: 0.93684912

00:06:00.970 --> 00:06:03.329 Texas City was higher in the Dr.
NOTE Confidence: 0.93684912

00:06:03.330 --> 00:06:03.998 Group,
NOTE Confidence: 0.93684912

00:06:03.998 --> 00:06:06.002 particularly with hematologic
NOTE Confidence: 0.93684912

00:06:06.002 --> 00:06:09.342 toxicities like anemia or neutropenia.

NOTE Confidence: 0.93684912

00:06:09.350 --> 00:06:10.466 And in this group,

NOTE Confidence: 0.93684912

00:06:10.466 --> 00:06:11.861 of course you worry about

NOTE Confidence: 0.93684912

00:06:11.861 --> 00:06:13.309 infections with this neutropenia,

NOTE Confidence: 0.93684912

00:06:13.310 --> 00:06:15.558 but they did not see an increase in

NOTE Confidence: 0.93684912

00:06:15.558 --> 00:06:17.950 grade 3 above infections in the Dr.

NOTE Confidence: 0.93684912

00:06:17.950 --> 00:06:19.980 Group compared to the R group and

NOTE Confidence: 0.93684912

00:06:19.980 --> 00:06:22.054 even when looking at patients who are

NOTE Confidence: 0.93684912

00:06:22.054 --> 00:06:24.050 very frail with scores of four and.

NOTE Confidence: 0.93684912

00:06:24.050 --> 00:06:24.477 Five,

NOTE Confidence: 0.93684912

00:06:24.477 --> 00:06:27.466 there was no difference in grade 3

NOTE Confidence: 0.93684912

00:06:27.466 --> 00:06:29.756 infections, so this is reassuring.

NOTE Confidence: 0.93684912

00:06:29.756 --> 00:06:31.148 So in conclusion,

NOTE Confidence: 0.93684912

00:06:31.150 --> 00:06:33.630 I think it is time to rethink duration

NOTE Confidence: 0.93684912

00:06:33.630 --> 00:06:35.829 deaths methadone especially for outpatients,

NOTE Confidence: 0.93684912

00:06:35.830 --> 00:06:39.268 longer follow-up of PFS is needed

NOTE Confidence: 0.93684912

00:06:39.270 --> 00:06:42.084 but higher MRD rates in the Dr.
NOTE Confidence: 0.93684912

00:06:42.090 --> 00:06:44.110 Group is very promising.
NOTE Confidence: 0.93684912

00:06:44.110 --> 00:06:47.500 I think the better comparator to Dr.
NOTE Confidence: 0.93684912

00:06:47.500 --> 00:06:50.034 like DRD and Maya would be a
NOTE Confidence: 0.93684912

00:06:50.034 --> 00:06:52.119 would have been a better design.
NOTE Confidence: 0.93684912

00:06:52.119 --> 00:06:52.368 However,
NOTE Confidence: 0.93684912

00:06:52.368 --> 00:06:53.862 this was not the standard of
NOTE Confidence: 0.93684912

00:06:53.862 --> 00:06:55.229 care when this was designed.
NOTE Confidence: 0.93684912

00:06:55.230 --> 00:06:57.510 They are going to be there are going
NOTE Confidence: 0.93684912

00:06:57.510 --> 00:06:59.898 to have a retrospective comparison.
NOTE Confidence: 0.93684912

00:06:59.900 --> 00:07:02.684 To the main study in the frail population,
NOTE Confidence: 0.93684912

00:07:02.690 --> 00:07:04.602 I think you know in you know right
NOTE Confidence: 0.93684912

00:07:04.602 --> 00:07:06.520 now when you see patients in clinic
NOTE Confidence: 0.93684912

00:07:06.520 --> 00:07:08.869 when you have that very frail over 80
NOTE Confidence: 0.93684912

00:07:08.869 --> 00:07:10.669 year old patient where you're really
NOTE Confidence: 0.93684912

00:07:10.669 --> 00:07:13.050 not sure about triple drug induction

NOTE Confidence: 0.93684912

00:07:13.050 --> 00:07:15.830 and you're thinking about a doublets.

NOTE Confidence: 0.93684912

00:07:15.830 --> 00:07:17.998 I would choose Dara Rev with a short

NOTE Confidence: 0.93684912

00:07:17.998 --> 00:07:20.407 duration of steroids as opposed to Rev Deck.

NOTE Confidence: 0.93684912

00:07:20.410 --> 00:07:22.986 So I I do think it's meaningful

NOTE Confidence: 0.93684912

00:07:22.986 --> 00:07:25.460 for for our practice today.

NOTE Confidence: 0.93684912

00:07:25.460 --> 00:07:27.833 The next set of subgroups I want

NOTE Confidence: 0.93684912

00:07:27.833 --> 00:07:30.343 to talk about another area of very

NOTE Confidence: 0.93684912

00:07:30.343 --> 00:07:33.065 high unmet need is the high risk

NOTE Confidence: 0.93684912

00:07:33.065 --> 00:07:35.680 population where we really have

NOTE Confidence: 0.93684912

00:07:35.680 --> 00:07:37.772 limited randomized studies guiding

NOTE Confidence: 0.8340638283333333

00:07:37.780 --> 00:07:38.740 our treatment.

NOTE Confidence: 0.8340638283333333

00:07:38.740 --> 00:07:41.857 The only randomized study was a -,

NOTE Confidence: 0.8340638283333333

00:07:41.857 --> 00:07:44.251 1 and this was evaluated the

NOTE Confidence: 0.8340638283333333

00:07:44.251 --> 00:07:47.085 addition of ELOTUZUMAB to Velcade

NOTE Confidence: 0.8340638283333333

00:07:47.085 --> 00:07:49.429 REVLIMID index methadone VRD.

NOTE Confidence: 0.8340638283333333

00:07:49.430 --> 00:07:51.850 Now we know we need to do better than VRD,
NOTE Confidence: 0.834063828333333

00:07:51.850 --> 00:07:53.326 but how do we do it?
NOTE Confidence: 0.834063828333333

00:07:53.330 --> 00:07:56.204 So one appealing option was switching
NOTE Confidence: 0.834063828333333

00:07:56.204 --> 00:07:58.670 out the VELCADE with carfilzomib
NOTE Confidence: 0.834063828333333

00:07:58.670 --> 00:08:01.506 which is a more potent proteasome
NOTE Confidence: 0.834063828333333

00:08:01.506 --> 00:08:03.986 inhibitor and outperform VELCADE in
NOTE Confidence: 0.834063828333333

00:08:03.986 --> 00:08:05.970 the relapsed refractory setting.
NOTE Confidence: 0.834063828333333

00:08:05.970 --> 00:08:06.499 Additionally,
NOTE Confidence: 0.834063828333333

00:08:06.499 --> 00:08:09.673 there was phase two studies showing
NOTE Confidence: 0.834063828333333

00:08:09.673 --> 00:08:12.369 high MRD negative rates in KRd.
NOTE Confidence: 0.834063828333333

00:08:12.370 --> 00:08:14.674 So it made sense to compare VRD to
NOTE Confidence: 0.834063828333333

00:08:14.674 --> 00:08:17.452 card and they did this in an endurance
NOTE Confidence: 0.834063828333333

00:08:17.452 --> 00:08:19.280 the endurance study and they.
NOTE Confidence: 0.834063828333333

00:08:19.280 --> 00:08:20.840 Actually did not find superiority
NOTE Confidence: 0.834063828333333

00:08:20.840 --> 00:08:22.650 of care due to the Rd.
NOTE Confidence: 0.834063828333333

00:08:22.650 --> 00:08:26.226 but they excluded high risk patients.

NOTE Confidence: 0.834063828333333
00:08:26.230 --> 00:08:28.071 So that question about how do we
NOTE Confidence: 0.834063828333333
00:08:28.071 --> 00:08:29.521 better improve our induction in
NOTE Confidence: 0.834063828333333
00:08:29.521 --> 00:08:31.345 the high risk patients was not
NOTE Confidence: 0.834063828333333
00:08:31.345 --> 00:08:32.752 really answered by this study.
NOTE Confidence: 0.834063828333333
00:08:32.752 --> 00:08:35.044 But people have not abandoned care
NOTE Confidence: 0.834063828333333
00:08:35.044 --> 00:08:37.462 being in in high risk patients
NOTE Confidence: 0.834063828333333
00:08:37.462 --> 00:08:39.447 for a variety of reasons.
NOTE Confidence: 0.834063828333333
00:08:39.450 --> 00:08:41.724 But in the memorial Stone Kettering
NOTE Confidence: 0.834063828333333
00:08:41.724 --> 00:08:43.850 Group where they are earlier,
NOTE Confidence: 0.834063828333333
00:08:43.850 --> 00:08:45.426 they were early adapters
NOTE Confidence: 0.834063828333333
00:08:45.426 --> 00:08:46.608 of Carradine induction.
NOTE Confidence: 0.834063828333333
00:08:46.610 --> 00:08:48.682 They were able to do a retrospective
NOTE Confidence: 0.834063828333333
00:08:48.682 --> 00:08:50.399 analysis and this was presented.
NOTE Confidence: 0.834063828333333
00:08:50.400 --> 00:08:53.248 Doctor Tan in this years ash of Care
NOTE Confidence: 0.834063828333333
00:08:53.248 --> 00:08:56.098 D versus verdine high risk myeloma.
NOTE Confidence: 0.834063828333333

00:08:56.100 --> 00:08:57.828 Their inclusion criteria for
NOTE Confidence: 0.8340638283333333

00:08:57.828 --> 00:08:59.988 high risk included having gain
NOTE Confidence: 0.8340638283333333

00:08:59.988 --> 00:09:01.748 of 1 Q translocations
NOTE Confidence: 0.7241738883333333

00:09:04.050 --> 00:09:07.574 41414161420 and deletion 17P.
NOTE Confidence: 0.7241738883333333

00:09:07.574 --> 00:09:10.036 They identified 154
NOTE Confidence: 0.7241738883333333

00:09:10.036 --> 00:09:12.820 patients in this category.
NOTE Confidence: 0.7241738883333333

00:09:12.820 --> 00:09:16.859 6067 had VRD and 87 had KRD.
NOTE Confidence: 0.7241738883333333

00:09:16.860 --> 00:09:19.681 About 50% of each of these groups
NOTE Confidence: 0.7241738883333333

00:09:19.681 --> 00:09:22.160 underwent early stem cell transplant.
NOTE Confidence: 0.7241738883333333

00:09:22.160 --> 00:09:23.865 Their primary endpoint was progression
NOTE Confidence: 0.7241738883333333

00:09:23.865 --> 00:09:25.959 free survival and they also looked
NOTE Confidence: 0.7241738883333333

00:09:25.959 --> 00:09:27.599 at response rate including MRD,
NOTE Confidence: 0.7241738883333333

00:09:27.600 --> 00:09:30.730 negative rate and overall survival.
NOTE Confidence: 0.7241738883333333

00:09:30.730 --> 00:09:32.506 So this is the patient characteristics.
NOTE Confidence: 0.7241738883333333

00:09:32.510 --> 00:09:34.170 A few things to highlight.
NOTE Confidence: 0.7241738883333333

00:09:34.170 --> 00:09:37.290 The carotid group were younger

NOTE Confidence: 0.724173888333333
00:09:37.290 --> 00:09:39.810 and then I want to look at the
NOTE Confidence: 0.724173888333333
00:09:39.810 --> 00:09:40.769 cytogenetic characteristics here
NOTE Confidence: 0.724173888333333
00:09:40.769 --> 00:09:42.631 just to see who are dealing with
NOTE Confidence: 0.724173888333333
00:09:42.631 --> 00:09:44.475 majority of the patients who are high
NOTE Confidence: 0.724173888333333
00:09:44.475 --> 00:09:46.534 risk or high risk by definition of
NOTE Confidence: 0.724173888333333
00:09:46.534 --> 00:09:48.544 chromosome 1Q gain or amplification,
NOTE Confidence: 0.724173888333333
00:09:48.550 --> 00:09:50.181 which is not unusual because this is
NOTE Confidence: 0.724173888333333
00:09:50.181 --> 00:09:52.327 one of the more common findings we see.
NOTE Confidence: 0.724173888333333
00:09:52.330 --> 00:09:54.286 The second most common was deletion
NOTE Confidence: 0.724173888333333
00:09:54.290 --> 00:09:56.444 17P and importantly about 1/4 of
NOTE Confidence: 0.724173888333333
00:09:56.444 --> 00:09:58.918 the patients of E in each group
NOTE Confidence: 0.724173888333333
00:09:58.918 --> 00:10:00.832 had two or more high risk.
NOTE Confidence: 0.724173888333333
00:10:00.840 --> 00:10:01.749 The genetic abnormalities,
NOTE Confidence: 0.724173888333333
00:10:01.749 --> 00:10:03.870 and this is now called the double
NOTE Confidence: 0.724173888333333
00:10:03.923 --> 00:10:05.792 hit or the ultra high risk patients
NOTE Confidence: 0.724173888333333

00:10:05.792 --> 00:10:07.360 which really have poor outcomes.
NOTE Confidence: 0.724173888333333

00:10:07.360 --> 00:10:09.370 So this is the response rates
NOTE Confidence: 0.724173888333333

00:10:09.370 --> 00:10:11.340 and the median PFS results.
NOTE Confidence: 0.724173888333333

00:10:11.340 --> 00:10:13.500 You see higher CR rates with
NOTE Confidence: 0.724173888333333

00:10:13.500 --> 00:10:14.940 KRD compared to VRD,
NOTE Confidence: 0.724173888333333

00:10:14.940 --> 00:10:18.918 higher MRD negative rates by flow,
NOTE Confidence: 0.724173888333333

00:10:18.920 --> 00:10:20.876 but it was not statistically significant.
NOTE Confidence: 0.724173888333333

00:10:20.880 --> 00:10:22.965 I think the most impressive
NOTE Confidence: 0.724173888333333

00:10:22.965 --> 00:10:24.633 results is the PFS,
NOTE Confidence: 0.724173888333333

00:10:24.640 --> 00:10:28.412 the KD having a median of 71 months
NOTE Confidence: 0.724173888333333

00:10:28.412 --> 00:10:31.950 compared to 41 months and this
NOTE Confidence: 0.724173888333333

00:10:31.950 --> 00:10:33.925 was you know highly statistical
NOTE Confidence: 0.724173888333333

00:10:33.925 --> 00:10:35.965 significance and they also saw
NOTE Confidence: 0.724173888333333

00:10:35.965 --> 00:10:37.537 an overall survival benefit.
NOTE Confidence: 0.724173888333333

00:10:37.540 --> 00:10:39.640 The five year estimate of
NOTE Confidence: 0.724173888333333

00:10:39.640 --> 00:10:41.076 85% compared to 63%.

NOTE Confidence: 0.724173888333333
00:10:41.076 --> 00:10:44.558 I want to just point out here in the
NOTE Confidence: 0.724173888333333
00:10:44.558 --> 00:10:47.048 ENDURANCE study remembers it is non
NOTE Confidence: 0.724173888333333
00:10:47.048 --> 00:10:49.820 high risk patients the PFS of both
NOTE Confidence: 0.724173888333333
00:10:49.820 --> 00:10:52.105 arms was 30-4 months and it's not
NOTE Confidence: 0.724173888333333
00:10:52.105 --> 00:10:54.492 quite clear why in this high risk
NOTE Confidence: 0.724173888333333
00:10:54.492 --> 00:10:56.874 populations that PFS is actually higher.
NOTE Confidence: 0.724173888333333
00:10:56.880 --> 00:10:58.455 So this was kind of brought up
NOTE Confidence: 0.724173888333333
00:10:58.455 --> 00:11:00.160 to the presenter and it was not
NOTE Confidence: 0.724173888333333
00:11:00.160 --> 00:11:01.380 there wasn't a great explanation
NOTE Confidence: 0.724173888333333
00:11:01.380 --> 00:11:03.000 but something to think about you
NOTE Confidence: 0.724173888333333
00:11:03.000 --> 00:11:05.624 know endurance was done in a in a a
NOTE Confidence: 0.724173888333333
00:11:05.624 --> 00:11:07.616 lot of community setting and this.
NOTE Confidence: 0.724173888333333
00:11:07.616 --> 00:11:11.234 Early as in a single institution,
NOTE Confidence: 0.724173888333333
00:11:11.234 --> 00:11:13.428 tertiary center.
NOTE Confidence: 0.724173888333333
00:11:13.430 --> 00:11:15.776 So next they did a multivariate
NOTE Confidence: 0.724173888333333

00:11:15.776 --> 00:11:17.777 analysis looking at different factors
NOTE Confidence: 0.724173888333333

00:11:17.777 --> 00:11:20.689 that are associated with better PFS and OS.
NOTE Confidence: 0.724173888333333

00:11:20.690 --> 00:11:23.005 So first type of inductions, OK,
NOTE Confidence: 0.724173888333333

00:11:23.005 --> 00:11:26.050 D is better, early transplant was better,
NOTE Confidence: 0.724173888333333

00:11:26.050 --> 00:11:28.000 having revised ISIS one compared to
NOTE Confidence: 0.724173888333333

00:11:28.000 --> 00:11:30.663 two or three was better and and that
NOTE Confidence: 0.724173888333333

00:11:30.663 --> 00:11:33.062 who are these revised access one in
NOTE Confidence: 0.724173888333333

00:11:33.062 --> 00:11:34.987 this high risk patient population,
NOTE Confidence: 0.724173888333333

00:11:34.990 --> 00:11:36.525 it's really those patients that
NOTE Confidence: 0.724173888333333

00:11:36.525 --> 00:11:38.060 have gained one cube because
NOTE Confidence: 0.724173888333333

00:11:38.120 --> 00:11:39.300 they were not included,
NOTE Confidence: 0.724173888333333

00:11:39.300 --> 00:11:41.948 it's not part of the revised ISS criteria.
NOTE Confidence: 0.724173888333333

00:11:41.950 --> 00:11:44.295 So you know who who these patients.
NOTE Confidence: 0.724173888333333

00:11:44.300 --> 00:11:47.024 And then the number of cycles
NOTE Confidence: 0.724173888333333

00:11:47.024 --> 00:11:49.465 having six or more induction
NOTE Confidence: 0.724173888333333

00:11:49.465 --> 00:11:52.627 cycles had better PFS and OS.

NOTE Confidence: 0.724173888333333
00:11:52.630 --> 00:11:53.545 So to summarize,
NOTE Confidence: 0.724173888333333
00:11:53.545 --> 00:11:55.375 I think the study is interesting.
NOTE Confidence: 0.724173888333333
00:11:55.380 --> 00:11:57.780 It does suggest that maybe Cardi could be
NOTE Confidence: 0.724173888333333
00:11:57.780 --> 00:11:59.919 better than VRD in high risk patients,
NOTE Confidence: 0.724173888333333
00:11:59.920 --> 00:12:02.433 but it is very limited by the
NOTE Confidence: 0.724173888333333
00:12:02.433 --> 00:12:04.389 retrospective nature of this design.
NOTE Confidence: 0.724173888333333
00:12:04.390 --> 00:12:06.462 I also think that you know they
NOTE Confidence: 0.724173888333333
00:12:06.462 --> 00:12:08.274 don't talk about which maintenance
NOTE Confidence: 0.724173888333333
00:12:08.274 --> 00:12:10.860 strategies they used and that will
NOTE Confidence: 0.724173888333333
00:12:10.860 --> 00:12:12.470 definitely impact PFS and OS.
NOTE Confidence: 0.724173888333333
00:12:12.470 --> 00:12:14.360 I think this study continues
NOTE Confidence: 0.724173888333333
00:12:14.360 --> 00:12:16.250 to support the notion that
NOTE Confidence: 0.889169216666667
00:12:16.326 --> 00:12:19.168 early transplant in high risk patients is
NOTE Confidence: 0.889169216666667
00:12:19.168 --> 00:12:22.178 beneficial and it does bring into question.
NOTE Confidence: 0.889169216666667
00:12:22.180 --> 00:12:25.225 What is the optimal number of induction
NOTE Confidence: 0.889169216666667

00:12:25.225 --> 00:12:27.659 treatments in high risk patients?
NOTE Confidence: 0.889169216666667

00:12:27.660 --> 00:12:30.228 Next I want to move to a more
NOTE Confidence: 0.889169216666667

00:12:30.228 --> 00:12:31.748 modern question is, you know,
NOTE Confidence: 0.889169216666667

00:12:31.748 --> 00:12:33.218 now that we're using quadruplex,
NOTE Confidence: 0.889169216666667

00:12:33.220 --> 00:12:35.537 how do high risk patients fare with
NOTE Confidence: 0.889169216666667

00:12:35.537 --> 00:12:37.659 the most commonly used quadruplets,
NOTE Confidence: 0.889169216666667

00:12:37.660 --> 00:12:39.409 the Dara VRD.
NOTE Confidence: 0.889169216666667

00:12:39.409 --> 00:12:43.176 So Dara VRD was studied in the Griffin study,
NOTE Confidence: 0.889169216666667

00:12:43.180 --> 00:12:45.880 which compared the addition of Dara
NOTE Confidence: 0.889169216666667

00:12:45.880 --> 00:12:49.209 to VRD in transplant eligible patients.
NOTE Confidence: 0.889169216666667

00:12:49.210 --> 00:12:51.632 In all patients they saw that there
NOTE Confidence: 0.889169216666667

00:12:51.632 --> 00:12:54.167 were higher MRD rates and also
NOTE Confidence: 0.889169216666667

00:12:54.167 --> 00:12:56.067 progression free survival benefit.
NOTE Confidence: 0.889169216666667

00:12:56.070 --> 00:12:57.786 But again this isn't all patients.
NOTE Confidence: 0.889169216666667

00:12:57.790 --> 00:12:59.925 There are only 15% of those patients
NOTE Confidence: 0.889169216666667

00:12:59.925 --> 00:13:02.069 and study that were high risk

NOTE Confidence: 0.889169216666667
00:13:02.069 --> 00:13:04.014 cytogenetics by the traditional high
NOTE Confidence: 0.889169216666667
00:13:04.014 --> 00:13:05.870 risk features like deletion 17,
NOTE Confidence: 0.889169216666667
00:13:05.870 --> 00:13:09.750 translocation 414 and four 416.
NOTE Confidence: 0.889169216666667
00:13:09.750 --> 00:13:13.754 So the Doctor Charity wanted to evaluate
NOTE Confidence: 0.889169216666667
00:13:13.754 --> 00:13:16.972 evaluated this subset group in the
NOTE Confidence: 0.889169216666667
00:13:16.972 --> 00:13:20.262 Griffin to really hone in on different
NOTE Confidence: 0.889169216666667
00:13:20.360 --> 00:13:23.870 high risk categories in the Griffin study.
NOTE Confidence: 0.889169216666667
00:13:23.870 --> 00:13:25.394 And I want to.
NOTE Confidence: 0.889169216666667
00:13:25.394 --> 00:13:26.918 Really it's a busy,
NOTE Confidence: 0.889169216666667
00:13:26.920 --> 00:13:27.860 a little bit busy slide,
NOTE Confidence: 0.889169216666667
00:13:27.860 --> 00:13:29.778 but let's just focus in on the
NOTE Confidence: 0.889169216666667
00:13:29.778 --> 00:13:31.333 side the genetic risk categories
NOTE Confidence: 0.889169216666667
00:13:31.333 --> 00:13:33.664 here as I highlighted they as I
NOTE Confidence: 0.889169216666667
00:13:33.664 --> 00:13:35.579 mentioned the initial high risk risk
NOTE Confidence: 0.889169216666667
00:13:35.579 --> 00:13:37.780 category were very few in both arms,
NOTE Confidence: 0.889169216666667

00:13:37.780 --> 00:13:40.160 but then they revised or high risk
NOTE Confidence: 0.889169216666667

00:13:40.160 --> 00:13:42.408 category to include chromosome abnormality
NOTE Confidence: 0.889169216666667

00:13:42.408 --> 00:13:44.713 and that really increased their,
NOTE Confidence: 0.889169216666667

00:13:44.720 --> 00:13:47.370 their patient population from 16
NOTE Confidence: 0.889169216666667

00:13:47.370 --> 00:13:50.378 to 42 patients in the Dara VRD and
NOTE Confidence: 0.889169216666667

00:13:50.378 --> 00:13:53.970 14 to 37 patients and then they
NOTE Confidence: 0.889169216666667

00:13:53.970 --> 00:13:56.406 categorize patients having zero.
NOTE Confidence: 0.889169216666667

00:13:56.410 --> 00:13:57.830 So no high risk features,
NOTE Confidence: 0.889169216666667

00:13:57.830 --> 00:13:58.802 HCA 1,
NOTE Confidence: 0.889169216666667

00:13:58.802 --> 00:14:01.232 high risk cell genetic abnormality
NOTE Confidence: 0.889169216666667

00:14:01.232 --> 00:14:05.179 or two or more as we call the
NOTE Confidence: 0.889169216666667

00:14:05.179 --> 00:14:07.087 ultra high risk patients.
NOTE Confidence: 0.889169216666667

00:14:07.090 --> 00:14:09.842 Clearly you can see the PFS in patients
NOTE Confidence: 0.889169216666667

00:14:09.842 --> 00:14:12.654 who are standard risk didn't seem to
NOTE Confidence: 0.889169216666667

00:14:12.654 --> 00:14:15.290 differ much between the two groups.
NOTE Confidence: 0.889169216666667

00:14:15.290 --> 00:14:17.474 Both of them had were were not reached

NOTE Confidence: 0.889169216666667
00:14:17.474 --> 00:14:19.609 in the meeting in the 15 months.
NOTE Confidence: 0.889169216666667
00:14:19.610 --> 00:14:21.350 Clearly the ultra high risk
NOTE Confidence: 0.889169216666667
00:14:21.350 --> 00:14:23.544 patients are too small to really
NOTE Confidence: 0.889169216666667
00:14:23.544 --> 00:14:25.479 make any conclusions about only
NOTE Confidence: 0.889169216666667
00:14:25.479 --> 00:14:27.690 10 patients in eight patients.
NOTE Confidence: 0.889169216666667
00:14:27.690 --> 00:14:30.290 But in the high risk in the one
NOTE Confidence: 0.889169216666667
00:14:30.290 --> 00:14:32.054 high risk cytogenetic abnormality
NOTE Confidence: 0.889169216666667
00:14:32.054 --> 00:14:34.629 group there was an improvement
NOTE Confidence: 0.889169216666667
00:14:34.629 --> 00:14:37.850 in PFS not reached compared to.
NOTE Confidence: 0.889169216666667
00:14:37.850 --> 00:14:38.718 48 months,
NOTE Confidence: 0.889169216666667
00:14:38.718 --> 00:14:41.756 and this is the only subgroup here
NOTE Confidence: 0.889169216666667
00:14:41.756 --> 00:14:44.682 that actually does not cross the
NOTE Confidence: 0.889169216666667
00:14:44.682 --> 00:14:47.094 hazard ratio does not cross one.
NOTE Confidence: 0.889169216666667
00:14:47.100 --> 00:14:48.766 So a different way of looking at
NOTE Confidence: 0.889169216666667
00:14:48.766 --> 00:14:50.848 the same data, if you're you know,
NOTE Confidence: 0.889169216666667

00:14:50.848 --> 00:14:52.216 a more visual person,
NOTE Confidence: 0.889169216666667

00:14:52.220 --> 00:14:56.245 is looking at the PFS curves and.
NOTE Confidence: 0.889169216666667

00:14:56.250 --> 00:14:59.080 What I want to show here in the kind of
NOTE Confidence: 0.889169216666667

00:14:59.160 --> 00:15:01.701 medium purple line the dare RVD with
NOTE Confidence: 0.889169216666667

00:15:01.701 --> 00:15:04.469 one high risk staging netic feature.
NOTE Confidence: 0.889169216666667

00:15:04.470 --> 00:15:08.326 Compare that to this green dotted line here,
NOTE Confidence: 0.889169216666667

00:15:08.330 --> 00:15:12.145 the derivative with sorry with VRD
NOTE Confidence: 0.889169216666667

00:15:12.145 --> 00:15:14.560 with one high risk feature there's a
NOTE Confidence: 0.889169216666667

00:15:14.636 --> 00:15:17.006 clear separation of the PFS curves,
NOTE Confidence: 0.889169216666667

00:15:17.010 --> 00:15:19.600 while there is really not a big
NOTE Confidence: 0.889169216666667

00:15:19.600 --> 00:15:21.184 difference with those patients
NOTE Confidence: 0.889169216666667

00:15:21.184 --> 00:15:23.572 who are standard risk and clearly
NOTE Confidence: 0.889169216666667

00:15:23.572 --> 00:15:25.960 the ultra high risk due poorly.
NOTE Confidence: 0.889169216666667

00:15:25.960 --> 00:15:28.216 Now look at the graph on the right.
NOTE Confidence: 0.889169216666667

00:15:28.220 --> 00:15:30.236 These are these are the amplification
NOTE Confidence: 0.889169216666667

00:15:30.236 --> 00:15:33.709 or gain of 1 Q and the grasp is actually

NOTE Confidence: 0.889169216666667
00:15:33.709 --> 00:15:36.005 pretty identical to the ones with
NOTE Confidence: 0.889169216666667
00:15:36.005 --> 00:15:38.573 the one high risk hydrogenic abnormality,
NOTE Confidence: 0.89576314625
00:15:38.580 --> 00:15:41.136 which really showed you who those
NOTE Confidence: 0.89576314625
00:15:41.136 --> 00:15:43.376 patients are. So in conclusion,
NOTE Confidence: 0.89576314625
00:15:43.376 --> 00:15:46.508 I think this analysis shows that Dara
NOTE Confidence: 0.89576314625
00:15:46.508 --> 00:15:49.490 VRD seemed to outperform VRD in high
NOTE Confidence: 0.89576314625
00:15:49.576 --> 00:15:52.607 risk patients harbouring gain of 1 Q.
NOTE Confidence: 0.89576314625
00:15:52.610 --> 00:15:55.865 High risk patients with more than two
NOTE Confidence: 0.89576314625
00:15:55.865 --> 00:15:57.830 cytogenetic abnormalities do poorly,
NOTE Confidence: 0.89576314625
00:15:57.830 --> 00:16:00.356 and we can't make any conclusions
NOTE Confidence: 0.89576314625
00:16:00.356 --> 00:16:02.474 for this analysis because of
NOTE Confidence: 0.89576314625
00:16:02.474 --> 00:16:04.259 the numbers were too small.
NOTE Confidence: 0.89576314625
00:16:04.260 --> 00:16:06.997 So this brings me to this category
NOTE Confidence: 0.89576314625
00:16:06.997 --> 00:16:09.944 of ultra high risk myeloma and the
NOTE Confidence: 0.89576314625
00:16:09.944 --> 00:16:12.408 optimum study was very clever study in
NOTE Confidence: 0.89576314625

00:16:12.408 --> 00:16:15.158 the UK they it was a screening study.
NOTE Confidence: 0.89576314625

00:16:15.160 --> 00:16:17.026 So anyone in multiple UK centers
NOTE Confidence: 0.89576314625

00:16:17.026 --> 00:16:19.079 who had the who's being worked
NOTE Confidence: 0.89576314625

00:16:19.079 --> 00:16:21.690 up for myeloma or was offered the
NOTE Confidence: 0.89576314625

00:16:21.690 --> 00:16:23.712 participation in the study and they
NOTE Confidence: 0.89576314625

00:16:23.712 --> 00:16:25.755 screen patients for high risk features,
NOTE Confidence: 0.89576314625

00:16:25.755 --> 00:16:27.575 they're they're inclusion was
NOTE Confidence: 0.89576314625

00:16:27.575 --> 00:16:29.395 to be double hit.
NOTE Confidence: 0.89576314625

00:16:29.400 --> 00:16:32.696 So you have to have two of the
NOTE Confidence: 0.89576314625

00:16:32.696 --> 00:16:33.913 following translocation 4141416.
NOTE Confidence: 0.89576314625

00:16:33.913 --> 00:16:35.878 Station one gain of 1,
NOTE Confidence: 0.89576314625

00:16:35.880 --> 00:16:38.728 so deletion one peak gain of 1Q and
NOTE Confidence: 0.89576314625

00:16:38.728 --> 00:16:41.478 deletion 17P or high risk gene profile
NOTE Confidence: 0.89576314625

00:16:41.478 --> 00:16:45.109 or if you had plasma cell leukemia,
NOTE Confidence: 0.89576314625

00:16:45.110 --> 00:16:47.390 which really is these patients
NOTE Confidence: 0.89576314625

00:16:47.390 --> 00:16:49.670 are excluded from every study

NOTE Confidence: 0.89576314625

00:16:49.670 --> 00:16:51.706 they identified 107 patients,

NOTE Confidence: 0.89576314625

00:16:51.706 --> 00:16:55.640 ten of which had plasma cell leukemia.

NOTE Confidence: 0.89576314625

00:16:55.640 --> 00:16:56.960 So there's a few things going

NOTE Confidence: 0.89576314625

00:16:56.960 --> 00:16:57.840 on in this study.

NOTE Confidence: 0.89576314625

00:16:57.840 --> 00:16:59.768 I want to focus first on the study

NOTE Confidence: 0.89576314625

00:16:59.768 --> 00:17:01.298 design of the optimum study,

NOTE Confidence: 0.89576314625

00:17:01.300 --> 00:17:02.938 which you talked about up here.

NOTE Confidence: 0.89576314625

00:17:02.940 --> 00:17:06.236 On top, they use five drugs in induction.

NOTE Confidence: 0.89576314625

00:17:06.240 --> 00:17:09.719 So they added cytotoxin to Dara VRD.

NOTE Confidence: 0.89576314625

00:17:09.720 --> 00:17:12.080 They added VELCADE in the

NOTE Confidence: 0.89576314625

00:17:12.080 --> 00:17:13.496 Peri transplant period.

NOTE Confidence: 0.89576314625

00:17:13.500 --> 00:17:16.468 They used six cycles of Dara VRD

NOTE Confidence: 0.89576314625

00:17:16.468 --> 00:17:19.788 induction and then 12 more cycles of

NOTE Confidence: 0.89576314625

00:17:19.788 --> 00:17:22.238 Dara RVD in extended consolidation,

NOTE Confidence: 0.89576314625

00:17:22.240 --> 00:17:24.288 so basically excluding steroids

NOTE Confidence: 0.89576314625

00:17:24.288 --> 00:17:25.824 in another year.
NOTE Confidence: 0.89576314625

00:17:25.830 --> 00:17:28.335 Of consolidation to and then
NOTE Confidence: 0.89576314625

00:17:28.335 --> 00:17:30.840 there are in until progression
NOTE Confidence: 0.89576314625

00:17:30.932 --> 00:17:34.142 and notably they're not using a
NOTE Confidence: 0.89576314625

00:17:34.142 --> 00:17:36.282 proteasome inhibitor long term.
NOTE Confidence: 0.89576314625

00:17:36.290 --> 00:17:38.642 So ideally the authors would love
NOTE Confidence: 0.89576314625

00:17:38.642 --> 00:17:41.689 to have done a randomized study,
NOTE Confidence: 0.89576314625

00:17:41.690 --> 00:17:43.076 but there was no standard of care
NOTE Confidence: 0.89576314625

00:17:43.076 --> 00:17:44.480 for these ultra high risk patients.
NOTE Confidence: 0.89576314625

00:17:44.480 --> 00:17:45.650 They thought it was unethical,
NOTE Confidence: 0.89576314625

00:17:45.650 --> 00:17:46.868 so they did not do so.
NOTE Confidence: 0.89576314625

00:17:46.870 --> 00:17:48.250 So it's a single arm study,
NOTE Confidence: 0.89576314625

00:17:48.250 --> 00:17:50.608 but they were very much interested
NOTE Confidence: 0.89576314625

00:17:50.608 --> 00:17:52.644 in understanding how this would
NOTE Confidence: 0.89576314625

00:17:52.644 --> 00:17:54.639 compare to a genetically similar
NOTE Confidence: 0.89576314625

00:17:54.639 --> 00:17:56.830 group of patients with myeloma.

NOTE Confidence: 0.89576314625

00:17:56.830 --> 00:17:59.315 So they looked at their myeloma ex

NOTE Confidence: 0.89576314625

00:17:59.315 --> 00:18:02.433 study and they had genetic testing for

NOTE Confidence: 0.89576314625

00:18:02.433 --> 00:18:05.391 all these patients identified and identical.

NOTE Confidence: 0.89576314625

00:18:05.400 --> 00:18:07.068 Population with this ultra

NOTE Confidence: 0.89576314625

00:18:07.068 --> 00:18:08.319 high risk phenotype,

NOTE Confidence: 0.89576314625

00:18:08.320 --> 00:18:10.184 I'm not going to go into the details

NOTE Confidence: 0.89576314625

00:18:10.184 --> 00:18:11.973 of that study because I do think

NOTE Confidence: 0.89576314625

00:18:11.973 --> 00:18:13.880 it's an overall sub par comparator.

NOTE Confidence: 0.89576314625

00:18:13.880 --> 00:18:16.556 But it's just for numerical purposes

NOTE Confidence: 0.89576314625

00:18:16.556 --> 00:18:19.152 here that they used cytotoxin

NOTE Confidence: 0.89576314625

00:18:19.152 --> 00:18:22.400 REVLIMID decks or carfilzomib,

NOTE Confidence: 0.89576314625

00:18:22.400 --> 00:18:23.288 cytoxan, REVLIMID,

NOTE Confidence: 0.89576314625

00:18:23.288 --> 00:18:25.508 dexin induction transplant and then

NOTE Confidence: 0.89576314625

00:18:25.508 --> 00:18:27.521 either they got no maintenance

NOTE Confidence: 0.89576314625

00:18:27.521 --> 00:18:29.656 which is really not what we do

NOTE Confidence: 0.89576314625

00:18:29.656 --> 00:18:31.549 or REVLIMID maintenance so.
NOTE Confidence: 0.89576314625

00:18:31.550 --> 00:18:34.427 Their objectives of the studies to look
NOTE Confidence: 0.89576314625

00:18:34.427 --> 00:18:37.410 at MRD, to look at PFS and toxicity.
NOTE Confidence: 0.89576314625

00:18:37.410 --> 00:18:40.146 I do want to note this is quite an
NOTE Confidence: 0.89576314625

00:18:40.146 --> 00:18:42.383 intensive treatment and they did
NOTE Confidence: 0.89576314625

00:18:42.383 --> 00:18:44.247 have several fallouts dropouts.
NOTE Confidence: 0.89576314625

00:18:44.250 --> 00:18:46.970 So out of 107 patients,
NOTE Confidence: 0.89576314625

00:18:46.970 --> 00:18:51.230 only 74 patients completed consolidation too.
NOTE Confidence: 0.89576314625

00:18:51.230 --> 00:18:53.312 The dropouts in the induction transplant
NOTE Confidence: 0.89576314625

00:18:53.312 --> 00:18:55.163 section was due to intolerance
NOTE Confidence: 0.89576314625

00:18:55.163 --> 00:18:57.138 and dropout and consolidation was
NOTE Confidence: 0.89576314625

00:18:57.138 --> 00:18:59.250 due to progression of disease.
NOTE Confidence: 0.89576314625

00:18:59.250 --> 00:19:02.530 So this is MRD at different time points.
NOTE Confidence: 0.787925930526316

00:19:02.530 --> 00:19:04.665 You can see that the MRDD deepened
NOTE Confidence: 0.787925930526316

00:19:04.665 --> 00:19:06.970 as you move from end of induction
NOTE Confidence: 0.787925930526316

00:19:06.970 --> 00:19:08.966 to end of transplant at 63%.

NOTE Confidence: 0.787925930526316
00:19:08.966 --> 00:19:11.318 I don't want you to be discouraged
NOTE Confidence: 0.787925930526316
00:19:11.318 --> 00:19:13.643 by the lower percentage after
NOTE Confidence: 0.787925930526316
00:19:13.643 --> 00:19:16.273 end of consolidation because they
NOTE Confidence: 0.787925930526316
00:19:16.273 --> 00:19:18.350 mentioned there are dropouts.
NOTE Confidence: 0.787925930526316
00:19:18.350 --> 00:19:20.814 So you can see here 30% of the
NOTE Confidence: 0.787925930526316
00:19:20.814 --> 00:19:22.549 patients didn't reach that endpoint.
NOTE Confidence: 0.787925930526316
00:19:22.550 --> 00:19:24.746 So that's why you see numerically
NOTE Confidence: 0.787925930526316
00:19:24.746 --> 00:19:26.710 lower rates of MRD there.
NOTE Confidence: 0.787925930526316
00:19:26.710 --> 00:19:28.590 What is important we know
NOTE Confidence: 0.787925930526316
00:19:28.590 --> 00:19:30.470 sustain MRD is actually more.
NOTE Confidence: 0.787925930526316
00:19:30.470 --> 00:19:32.744 Relevance than just one time point
NOTE Confidence: 0.787925930526316
00:19:32.744 --> 00:19:34.580 of emerging negativity is that
NOTE Confidence: 0.787925930526316
00:19:34.580 --> 00:19:37.580 84% had sustained MRD negativity
NOTE Confidence: 0.787925930526316
00:19:37.580 --> 00:19:40.156 at the end of consolidation.
NOTE Confidence: 0.787925930526316
00:19:40.156 --> 00:19:43.710 So that is very important.
NOTE Confidence: 0.787925930526316

00:19:43.710 --> 00:19:45.922 Now this is the PFS course again
NOTE Confidence: 0.787925930526316

00:19:45.922 --> 00:19:47.984 I'm not surprised that the PFS
NOTE Confidence: 0.787925930526316

00:19:47.984 --> 00:19:49.724 is better with this optimum
NOTE Confidence: 0.787925930526316

00:19:49.724 --> 00:19:51.690 regiments than the the comparator.
NOTE Confidence: 0.787925930526316

00:19:51.690 --> 00:19:53.482 They did spread out in the in the
NOTE Confidence: 0.787925930526316

00:19:53.482 --> 00:19:55.452 myeloma X the ones that got prophesied
NOTE Confidence: 0.787925930526316

00:19:55.452 --> 00:19:57.217 that were not to secularism seemed
NOTE Confidence: 0.787925930526316

00:19:57.217 --> 00:19:59.169 to be a little bit better than not.
NOTE Confidence: 0.787925930526316

00:19:59.170 --> 00:20:01.380 Again not very surprising with
NOTE Confidence: 0.787925930526316

00:20:01.380 --> 00:20:03.590 produce some inhibitor but regardless
NOTE Confidence: 0.787925930526316

00:20:03.660 --> 00:20:05.766 I think it's very impressive the
NOTE Confidence: 0.787925930526316

00:20:05.766 --> 00:20:09.200 30 month PFS estimate of 77% and
NOTE Confidence: 0.787925930526316

00:20:09.200 --> 00:20:14.690 this does fare favorably to other.
NOTE Confidence: 0.787925930526316

00:20:14.690 --> 00:20:17.651 Other data out there for this really
NOTE Confidence: 0.787925930526316

00:20:17.651 --> 00:20:19.870 high risk patient population.
NOTE Confidence: 0.787925930526316

00:20:19.870 --> 00:20:21.054 In terms of toxicity,

NOTE Confidence: 0.787925930526316
00:20:21.054 --> 00:20:23.285 which is very relevant when people are
NOTE Confidence: 0.787925930526316
00:20:23.285 --> 00:20:25.270 getting this intense prolonged treatment,
NOTE Confidence: 0.787925930526316
00:20:25.270 --> 00:20:27.690 they showed you here the
NOTE Confidence: 0.787925930526316
00:20:27.690 --> 00:20:29.626 consolidation to adverse events.
NOTE Confidence: 0.787925930526316
00:20:29.630 --> 00:20:32.984 So there are some grade three side effects.
NOTE Confidence: 0.787925930526316
00:20:32.984 --> 00:20:34.569 There are not that many,
NOTE Confidence: 0.787925930526316
00:20:34.570 --> 00:20:37.495 most of them are hematological
NOTE Confidence: 0.787925930526316
00:20:37.495 --> 00:20:38.665 like neutropenia.
NOTE Confidence: 0.787925930526316
00:20:38.670 --> 00:20:41.670 There were some Grade 3 infections,
NOTE Confidence: 0.787925930526316
00:20:41.670 --> 00:20:42.338 about 12%,
NOTE Confidence: 0.787925930526316
00:20:42.338 --> 00:20:44.342 most of them being respiratory tract
NOTE Confidence: 0.787925930526316
00:20:44.342 --> 00:20:46.358 infections and they don't separate out,
NOTE Confidence: 0.787925930526316
00:20:46.360 --> 00:20:48.810 you know, the viruses from the bacteria,
NOTE Confidence: 0.787925930526316
00:20:48.810 --> 00:20:50.290 but that I think that would be relevant.
NOTE Confidence: 0.787925930526316
00:20:50.290 --> 00:20:53.706 Especially in the era of of a pandemic.
NOTE Confidence: 0.787925930526316

00:20:53.710 --> 00:20:55.936 So it seems to be fairly toggled.
NOTE Confidence: 0.787925930526316

00:20:55.940 --> 00:20:56.410 They did.
NOTE Confidence: 0.787925930526316

00:20:56.410 --> 00:21:00.840 One thing to note, they did allow for very.
NOTE Confidence: 0.787925930526316

00:21:00.840 --> 00:21:02.061 Flexible dose reductions,
NOTE Confidence: 0.787925930526316

00:21:02.061 --> 00:21:05.414 even for Grade 1 toxicity to allow patients
NOTE Confidence: 0.787925930526316

00:21:05.414 --> 00:21:08.030 to continue on treatment for longer.
NOTE Confidence: 0.787925930526316

00:21:08.030 --> 00:21:08.795 So in conclusion,
NOTE Confidence: 0.787925930526316

00:21:08.795 --> 00:21:10.580 I think these type of single ARM
NOTE Confidence: 0.787925930526316

00:21:10.634 --> 00:21:12.319 studies can serve as comparators
NOTE Confidence: 0.787925930526316

00:21:12.319 --> 00:21:14.366 for future randomized studies and of
NOTE Confidence: 0.787925930526316

00:21:14.366 --> 00:21:15.921 course balancing the efficacy and
NOTE Confidence: 0.787925930526316

00:21:15.921 --> 00:21:19.450 toxicity in this patient population.
NOTE Confidence: 0.787925930526316

00:21:19.450 --> 00:21:21.628 Now the last study I'm going to go into,
NOTE Confidence: 0.787925930526316

00:21:21.630 --> 00:21:23.443 I'm going to shift gears to a
NOTE Confidence: 0.787925930526316

00:21:23.443 --> 00:21:24.870 different subtype of high risk
NOTE Confidence: 0.787925930526316

00:21:24.870 --> 00:21:26.646 patients and these are the functional

NOTE Confidence: 0.787925930526316
00:21:26.646 --> 00:21:28.640 high risk myeloma and these are not
NOTE Confidence: 0.787925930526316
00:21:28.640 --> 00:21:30.205 the patients you know that they're
NOTE Confidence: 0.787925930526316
00:21:30.205 --> 00:21:31.710 high risk when you first see them,
NOTE Confidence: 0.787925930526316
00:21:31.710 --> 00:21:33.710 they they demonstrate themselves
NOTE Confidence: 0.787925930526316
00:21:33.710 --> 00:21:36.710 because they or they relapse early.
NOTE Confidence: 0.787925930526316
00:21:36.710 --> 00:21:39.062 So patients who have early relapse
NOTE Confidence: 0.787925930526316
00:21:39.062 --> 00:21:41.153 after transplant within one year
NOTE Confidence: 0.787925930526316
00:21:41.153 --> 00:21:42.527 have horrible prognosis.
NOTE Confidence: 0.787925930526316
00:21:42.530 --> 00:21:44.702 You see here 26 months overall
NOTE Confidence: 0.787925930526316
00:21:44.702 --> 00:21:46.580 survival compared to 91 months
NOTE Confidence: 0.787925930526316
00:21:46.580 --> 00:21:48.710 if you didn't have this early.
NOTE Confidence: 0.787925930526316
00:21:48.710 --> 00:21:49.718 About relapse,
NOTE Confidence: 0.787925930526316
00:21:49.718 --> 00:21:53.246 So what this Karma 2A study analyzed
NOTE Confidence: 0.787925930526316
00:21:53.246 --> 00:21:57.016 is the use of either cell or abukuma,
NOTE Confidence: 0.787925930526316
00:21:57.020 --> 00:21:59.054 which is the first CMA directed
NOTE Confidence: 0.787925930526316

00:21:59.054 --> 00:22:01.299 car T cell product for myeloma.

NOTE Confidence: 0.787925930526316

00:22:01.300 --> 00:22:03.995 They used it in this patient population.

NOTE Confidence: 0.787925930526316

00:22:04.000 --> 00:22:05.840 The inclusion criteria includes

NOTE Confidence: 0.787925930526316

00:22:05.840 --> 00:22:08.140 elaps 18 months after initiation

NOTE Confidence: 0.787925930526316

00:22:08.140 --> 00:22:09.909 of frontline therapy.

NOTE Confidence: 0.787925930526316

00:22:09.910 --> 00:22:12.442 And you had to have revilement

NOTE Confidence: 0.787925930526316

00:22:12.442 --> 00:22:13.286 based maintenance.

NOTE Confidence: 0.787925930526316

00:22:13.290 --> 00:22:15.474 The primary endpoint was a CR

NOTE Confidence: 0.787925930526316

00:22:15.474 --> 00:22:16.930 and secondary endpoints include

NOTE Confidence: 0.770254851538461

00:22:16.995 --> 00:22:18.249 duration of response,

NOTE Confidence: 0.770254851538461

00:22:18.250 --> 00:22:21.210 progression free survival and toxicity.

NOTE Confidence: 0.770254851538461

00:22:21.210 --> 00:22:22.635 So patient characteristics

NOTE Confidence: 0.770254851538461

00:22:22.635 --> 00:22:24.060 are presented here,

NOTE Confidence: 0.770254851538461

00:22:24.060 --> 00:22:25.395 few things to highlight in

NOTE Confidence: 0.770254851538461

00:22:25.395 --> 00:22:26.730 terms of high risk features.

NOTE Confidence: 0.770254851538461

00:22:26.730 --> 00:22:29.145 There were 32% high risk disease in

NOTE Confidence: 0.770254851538461
00:22:29.145 --> 00:22:31.080 this functionally high risk patients.
NOTE Confidence: 0.770254851538461
00:22:31.080 --> 00:22:35.136 There were 40% with missing data.
NOTE Confidence: 0.770254851538461
00:22:35.140 --> 00:22:37.636 It they did have information about
NOTE Confidence: 0.770254851538461
00:22:37.636 --> 00:22:39.758 their response to upfront therapy
NOTE Confidence: 0.770254851538461
00:22:39.758 --> 00:22:41.982 and 24% of the patients have CR
NOTE Confidence: 0.770254851538461
00:22:41.982 --> 00:22:44.000 to their first line of therapy.
NOTE Confidence: 0.770254851538461
00:22:44.000 --> 00:22:46.150 Most patients have progression of
NOTE Confidence: 0.770254851538461
00:22:46.150 --> 00:22:48.773 disease within 12 months of transplant
NOTE Confidence: 0.770254851538461
00:22:48.773 --> 00:22:51.538 and no patients were refractory to an
NOTE Confidence: 0.770254851538461
00:22:51.538 --> 00:22:54.240 anti CD 38 like there are two now.
NOTE Confidence: 0.770254851538461
00:22:54.240 --> 00:22:56.040 This is the efficacy data.
NOTE Confidence: 0.770254851538461
00:22:56.040 --> 00:22:58.713 The CRH which I think is the most relevant
NOTE Confidence: 0.770254851538461
00:22:58.713 --> 00:23:03.140 in terms of the response rate is 45%.
NOTE Confidence: 0.770254851538461
00:23:03.140 --> 00:23:04.600 Just put here in Gray,
NOTE Confidence: 0.770254851538461
00:23:04.600 --> 00:23:06.724 what is the CR rate that was seen in
NOTE Confidence: 0.770254851538461

00:23:06.724 --> 00:23:09.229 this agent in the relapse that heavily
NOTE Confidence: 0.770254851538461

00:23:09.229 --> 00:23:12.770 pretreated population which is 33%?
NOTE Confidence: 0.770254851538461

00:23:12.770 --> 00:23:14.555 Just like the other car T products,
NOTE Confidence: 0.770254851538461

00:23:14.560 --> 00:23:15.950 we see the deeper response,
NOTE Confidence: 0.770254851538461

00:23:15.950 --> 00:23:17.840 the longer duration of response.
NOTE Confidence: 0.770254851538461

00:23:17.840 --> 00:23:20.336 Overall, the median duration of the
NOTE Confidence: 0.770254851538461

00:23:20.336 --> 00:23:22.670 responder responding patients was 15 months,
NOTE Confidence: 0.770254851538461

00:23:22.670 --> 00:23:25.551 but if you had a CR then it goes to 23
NOTE Confidence: 0.770254851538461

00:23:25.551 --> 00:23:28.260 months and if you had a PR for example,
NOTE Confidence: 0.770254851538461

00:23:28.260 --> 00:23:29.940 it's as short as three months.
NOTE Confidence: 0.770254851538461

00:23:29.940 --> 00:23:33.030 So really depth of response
NOTE Confidence: 0.770254851538461

00:23:33.030 --> 00:23:34.884 is extremely important.
NOTE Confidence: 0.770254851538461

00:23:34.890 --> 00:23:38.030 PFS is roughly a year,
NOTE Confidence: 0.770254851538461

00:23:38.030 --> 00:23:40.172 so 11 months here which is quite
NOTE Confidence: 0.770254851538461

00:23:40.172 --> 00:23:43.105 similar to what was seen in the relapse
NOTE Confidence: 0.770254851538461

00:23:43.105 --> 00:23:44.661 refractory patient population and

NOTE Confidence: 0.770254851538461
00:23:44.661 --> 00:23:47.303 you know I think again this includes
NOTE Confidence: 0.770254851538461
00:23:47.303 --> 00:23:49.366 all those non responders as well.
NOTE Confidence: 0.770254851538461
00:23:49.366 --> 00:23:51.790 I think it would be interesting to see
NOTE Confidence: 0.770254851538461
00:23:51.857 --> 00:23:55.660 the PFS for those who are responding.
NOTE Confidence: 0.770254851538461
00:23:55.660 --> 00:23:57.068 In terms of toxicity,
NOTE Confidence: 0.770254851538461
00:23:57.068 --> 00:23:59.180 there was initial concern that when
NOTE Confidence: 0.770254851538461
00:23:59.249 --> 00:24:01.009 you're using these cartee products
NOTE Confidence: 0.770254851538461
00:24:01.009 --> 00:24:03.171 earlier in the line of treatment
NOTE Confidence: 0.770254851538461
00:24:03.171 --> 00:24:05.495 that the T cells might be fitter,
NOTE Confidence: 0.770254851538461
00:24:05.500 --> 00:24:07.690 they might be healthier and actually
NOTE Confidence: 0.770254851538461
00:24:07.690 --> 00:24:09.950 have higher toxicities like CRS
NOTE Confidence: 0.770254851538461
00:24:09.950 --> 00:24:12.500 and and the neurotoxicity icams,
NOTE Confidence: 0.770254851538461
00:24:12.500 --> 00:24:14.516 but they didn't see that in this study.
NOTE Confidence: 0.770254851538461
00:24:14.520 --> 00:24:16.938 So there were roughly the same
NOTE Confidence: 0.770254851538461
00:24:16.938 --> 00:24:19.407 amount of percentage of events in
NOTE Confidence: 0.770254851538461

00:24:19.407 --> 00:24:21.735 the CRS and the neurotoxicity group
NOTE Confidence: 0.770254851538461

00:24:21.735 --> 00:24:24.608 as was seen in the prior study
NOTE Confidence: 0.770254851538461

00:24:24.608 --> 00:24:26.623 and actually there were lower.
NOTE Confidence: 0.770254851538461

00:24:26.630 --> 00:24:29.552 Or at least numerically lower number
NOTE Confidence: 0.770254851538461

00:24:29.552 --> 00:24:33.176 of high grade events like grade 3/4 in
NOTE Confidence: 0.770254851538461

00:24:33.176 --> 00:24:35.738 both groups compared to the prior study.
NOTE Confidence: 0.770254851538461

00:24:35.738 --> 00:24:38.006 I do want to mention infections
NOTE Confidence: 0.770254851538461

00:24:38.006 --> 00:24:40.737 is still an issue of post party.
NOTE Confidence: 0.770254851538461

00:24:40.740 --> 00:24:44.314 There was a grade 3-4 infections at 22%
NOTE Confidence: 0.770254851538461

00:24:44.314 --> 00:24:47.466 and in fact 2 deaths from this with
NOTE Confidence: 0.770254851538461

00:24:47.466 --> 00:24:50.679 pneumonia and another from studemont sepsis.
NOTE Confidence: 0.770254851538461

00:24:50.680 --> 00:24:51.856 So in conclusion,
NOTE Confidence: 0.770254851538461

00:24:51.856 --> 00:24:53.424 in this functionally high
NOTE Confidence: 0.770254851538461

00:24:53.424 --> 00:24:54.600 risk patient population,
NOTE Confidence: 0.770254851538461

00:24:54.600 --> 00:24:56.628 either cell achieved 45% CR rates
NOTE Confidence: 0.770254851538461

00:24:56.628 --> 00:24:58.970 and this was higher than what was

NOTE Confidence: 0.770254851538461
00:24:58.970 --> 00:25:01.112 seen in the first line of therapy.
NOTE Confidence: 0.770254851538461
00:25:01.120 --> 00:25:02.341 For these patients.
NOTE Confidence: 0.770254851538461
00:25:02.341 --> 00:25:05.190 It seems that there are less grade
NOTE Confidence: 0.770254851538461
00:25:05.273 --> 00:25:08.148 3-4 toxicities compared to the
NOTE Confidence: 0.770254851538461
00:25:08.148 --> 00:25:09.873 relapse refractory population.
NOTE Confidence: 0.770254851538461
00:25:09.880 --> 00:25:12.424 The PFS seems similar to what was seen
NOTE Confidence: 0.770254851538461
00:25:12.424 --> 00:25:15.260 in the heavily pretreated population,
NOTE Confidence: 0.770254851538461
00:25:15.260 --> 00:25:17.255 but these patients are very high risk,
NOTE Confidence: 0.770254851538461
00:25:17.260 --> 00:25:18.890 they they are very difficult
NOTE Confidence: 0.770254851538461
00:25:18.890 --> 00:25:20.520 to treat and salvage so.
NOTE Confidence: 0.770254851538461
00:25:20.520 --> 00:25:22.344 I think we really need randomized
NOTE Confidence: 0.770254851538461
00:25:22.344 --> 00:25:24.719 study to see what is the best
NOTE Confidence: 0.770254851538461
00:25:24.719 --> 00:25:26.539 treatment for these patients and
NOTE Confidence: 0.770254851538461
00:25:26.539 --> 00:25:28.147 ideally identify those that have
NOTE Confidence: 0.770254851538461
00:25:28.147 --> 00:25:29.779 that will have a CR rate.
NOTE Confidence: 0.909416426

00:25:29.780 --> 00:25:33.140 So I want to close with this one last slide.

NOTE Confidence: 0.909416426

00:25:33.140 --> 00:25:35.300 This is what I think is the future.

NOTE Confidence: 0.909416426

00:25:35.300 --> 00:25:37.844 It's this risk adaptive therapy directed

NOTE Confidence: 0.909416426

00:25:37.844 --> 00:25:40.180 according to response type of study.

NOTE Confidence: 0.909416426

00:25:40.180 --> 00:25:42.700 This is the radar study that was presented

NOTE Confidence: 0.909416426

00:25:42.700 --> 00:25:44.928 by Doctor Wong from the UK don't want

NOTE Confidence: 0.909416426

00:25:44.928 --> 00:25:47.314 to go into the details of all this is

NOTE Confidence: 0.909416426

00:25:47.314 --> 00:25:49.748 a busy slide but the concept here is

NOTE Confidence: 0.909416426

00:25:49.748 --> 00:25:52.004 extremely important that you separate out

NOTE Confidence: 0.909416426

00:25:52.004 --> 00:25:54.478 the standard risk from the high risk,

NOTE Confidence: 0.909416426

00:25:54.480 --> 00:25:55.140 high risk patients.

NOTE Confidence: 0.909416426

00:25:55.140 --> 00:25:56.680 We don't want to stop treatment on,

NOTE Confidence: 0.909416426

00:25:56.680 --> 00:25:58.660 we need better treatments standard

NOTE Confidence: 0.909416426

00:25:58.660 --> 00:25:59.848 risk that have.

NOTE Confidence: 0.909416426

00:25:59.850 --> 00:26:02.482 MRD negative disease can maybe even stop

NOTE Confidence: 0.909416426

00:26:02.482 --> 00:26:03.984 treatment and standardized patients

NOTE Confidence: 0.909416426

00:26:03.984 --> 00:26:05.554 who don't achieve MRD negativity

NOTE Confidence: 0.909416426

00:26:05.554 --> 00:26:07.991 how is how are we going to deepen

NOTE Confidence: 0.909416426

00:26:07.991 --> 00:26:10.058 their response how are we going to

NOTE Confidence: 0.909416426

00:26:10.058 --> 00:26:12.326 get them together MRD negative state

NOTE Confidence: 0.909416426

00:26:12.326 --> 00:26:14.953 so you know when and randomizing

NOTE Confidence: 0.909416426

00:26:14.953 --> 00:26:17.313 doing a randomized fashion so.

NOTE Confidence: 0.909416426

00:26:17.320 --> 00:26:19.721 The this and other type studies like

NOTE Confidence: 0.909416426

00:26:19.721 --> 00:26:22.470 this are ongoing and I think the next

NOTE Confidence: 0.909416426

00:26:22.470 --> 00:26:25.034 decade hopefully we'll have an answer to

NOTE Confidence: 0.909416426

00:26:25.034 --> 00:26:27.758 how to personalize treatments for myeloma.

NOTE Confidence: 0.909416426

00:26:27.760 --> 00:26:30.950 And with that I will close my section of the

NOTE Confidence: 0.909416426

00:26:31.028 --> 00:26:34.148 talk and we'll move on to Doctor Brownings.

NOTE Confidence: 0.885277639166667

00:26:39.870 --> 00:26:41.802 OK, great. Well, thank you Doctor

NOTE Confidence: 0.885277639166667

00:26:41.802 --> 00:26:44.050 Barr and and welcome again everyone.

NOTE Confidence: 0.885277639166667

00:26:44.050 --> 00:26:46.378 My name is Sabrina Browning and with the

NOTE Confidence: 0.885277639166667

00:26:46.378 --> 00:26:48.505 remainder of our time that we have left,
NOTE Confidence: 0.885277639166667

00:26:48.510 --> 00:26:51.214 I'm going to review with you data on
NOTE Confidence: 0.885277639166667

00:26:51.214 --> 00:26:53.049 relapse refractory myeloma and we'll
NOTE Confidence: 0.885277639166667

00:26:53.049 --> 00:26:55.590 also briefly touch upon a new therapeutic
NOTE Confidence: 0.885277639166667

00:26:55.657 --> 00:26:57.687 in light chainer AL amyloidosis.
NOTE Confidence: 0.885277639166667

00:26:57.690 --> 00:27:00.308 And I have no disclosures to report.
NOTE Confidence: 0.885277639166667

00:27:00.310 --> 00:27:02.420 So a major focus in myeloma at
NOTE Confidence: 0.885277639166667

00:27:02.420 --> 00:27:05.121 Ash this year was the diverse and
NOTE Confidence: 0.885277639166667

00:27:05.121 --> 00:27:06.780 advancing immunotherapeutic landscape
NOTE Confidence: 0.885277639166667

00:27:06.780 --> 00:27:09.545 for relapse and refractory disease.
NOTE Confidence: 0.885277639166667

00:27:09.550 --> 00:27:12.678 And as you all are familiar B cell
NOTE Confidence: 0.885277639166667

00:27:12.678 --> 00:27:14.760 maturation antigen or BCMA has been
NOTE Confidence: 0.885277639166667

00:27:14.760 --> 00:27:16.650 a critical target on myeloma cells.
NOTE Confidence: 0.885277639166667

00:27:16.650 --> 00:27:18.729 And as Doctor Barr mentioned we now
NOTE Confidence: 0.885277639166667

00:27:18.729 --> 00:27:20.859 have two approved anti BCMA CAR T
NOTE Confidence: 0.885277639166667

00:27:20.859 --> 00:27:22.537 cell products eye to cell and cell

NOTE Confidence: 0.885277639166667
00:27:22.537 --> 00:27:24.633 to cell as well as an anti BCM A
NOTE Confidence: 0.885277639166667
00:27:24.633 --> 00:27:26.348 by specific antibody articles amab
NOTE Confidence: 0.885277639166667
00:27:26.348 --> 00:27:28.869 and while I won't cover this today.
NOTE Confidence: 0.885277639166667
00:27:28.870 --> 00:27:30.928 There was promising early phase data
NOTE Confidence: 0.885277639166667
00:27:30.928 --> 00:27:33.019 presented on the combination of teclis
NOTE Confidence: 0.885277639166667
00:27:33.019 --> 00:27:34.679 tamal with daratumumab and Lenalidomide
NOTE Confidence: 0.885277639166667
00:27:34.679 --> 00:27:36.398 and there are other combinations
NOTE Confidence: 0.885277639166667
00:27:36.398 --> 00:27:38.390 with this by specific antibody that
NOTE Confidence: 0.885277639166667
00:27:38.390 --> 00:27:40.080 are also actively being studied.
NOTE Confidence: 0.885277639166667
00:27:40.080 --> 00:27:43.274 As well as the number of new BCM ART
NOTE Confidence: 0.885277639166667
00:27:43.274 --> 00:27:45.139 invites but importantly the abstracts
NOTE Confidence: 0.885277639166667
00:27:45.139 --> 00:27:47.924 that I will focus on today with with
NOTE Confidence: 0.885277639166667
00:27:47.924 --> 00:27:50.312 you all highlight some T cell to
NOTE Confidence: 0.885277639166667
00:27:50.312 --> 00:27:51.876 redirection therapies that harness
NOTE Confidence: 0.885277639166667
00:27:51.876 --> 00:27:53.970 new myeloma cell antigen targets.
NOTE Confidence: 0.885277639166667

00:27:53.970 --> 00:27:56.670 And these include G protein coupled
NOTE Confidence: 0.885277639166667

00:27:56.670 --> 00:27:59.891 receptor family C Group 5 member D or
NOTE Confidence: 0.885277639166667

00:27:59.891 --> 00:28:03.370 what's referred to as GPRC 5D and SC
NOTE Confidence: 0.885277639166667

00:28:03.370 --> 00:28:06.794 receptor homologue 5 or FCR H5 as well
NOTE Confidence: 0.885277639166667

00:28:06.794 --> 00:28:08.720 as some non cellular therapies that
NOTE Confidence: 0.885277639166667

00:28:08.789 --> 00:28:11.039 help reverse tumor mediated immune.
NOTE Confidence: 0.885277639166667

00:28:11.040 --> 00:28:13.650 Paralysis that occurs in in myeloma,
NOTE Confidence: 0.885277639166667

00:28:13.650 --> 00:28:15.426 and these include the novel cereblon,
NOTE Confidence: 0.885277639166667

00:28:15.430 --> 00:28:16.639 Eli Gaze modulators,
NOTE Confidence: 0.885277639166667

00:28:16.639 --> 00:28:20.529 or what is referred to as as cell months.
NOTE Confidence: 0.885277639166667

00:28:20.530 --> 00:28:23.419 So to to start we will discuss the phase
NOTE Confidence: 0.885277639166667

00:28:23.419 --> 00:28:26.193 two results from the monumental one
NOTE Confidence: 0.885277639166667

00:28:26.193 --> 00:28:29.079 study which represented by Doctor Ajai
NOTE Confidence: 0.885277639166667

00:28:29.079 --> 00:28:31.707 Chari and this evaluates talked amab.
NOTE Confidence: 0.885277639166667

00:28:31.710 --> 00:28:34.833 Talked Amab is a first in class T cell
NOTE Confidence: 0.885277639166667

00:28:34.833 --> 00:28:37.406 bispecific antibody that targets GPRC 5D.

NOTE Confidence: 0.885277639166667
00:28:37.406 --> 00:28:39.374 And as previously discussed this is
NOTE Confidence: 0.885277639166667
00:28:39.374 --> 00:28:41.338 highly expressed on myeloma cells and
NOTE Confidence: 0.885277639166667
00:28:41.338 --> 00:28:43.210 thought to have limited expression on
NOTE Confidence: 0.885277639166667
00:28:43.268 --> 00:28:45.368 normal cells cells and that includes
NOTE Confidence: 0.885277639166667
00:28:45.368 --> 00:28:47.017 hematopoietic stem cells and in
NOTE Confidence: 0.885277639166667
00:28:47.017 --> 00:28:48.746 December of this past year the phase
NOTE Confidence: 0.885277639166667
00:28:48.746 --> 00:28:50.638 one data from the monumental study.
NOTE Confidence: 0.885277639166667
00:28:50.640 --> 00:28:53.146 Were published in the New England Journal
NOTE Confidence: 0.885277639166667
00:28:53.146 --> 00:28:54.976 and demonstrated an impressive overall
NOTE Confidence: 0.885277639166667
00:28:54.976 --> 00:28:58.020 response rate of 64 to 70% with both
NOTE Confidence: 0.885277639166667
00:28:58.020 --> 00:29:00.660 weekly and every other weekly dosing.
NOTE Confidence: 0.885277639166667
00:29:00.660 --> 00:29:02.620 And so for the phase two portion
NOTE Confidence: 0.885277639166667
00:29:02.620 --> 00:29:03.460 of the study,
NOTE Confidence: 0.885277639166667
00:29:03.460 --> 00:29:05.340 patients had to have an ECOG of zero
NOTE Confidence: 0.885277639166667
00:29:05.340 --> 00:29:07.102 to two with measurable disease and
NOTE Confidence: 0.885277639166667

00:29:07.102 --> 00:29:09.440 three or more lines of prior therapy.
NOTE Confidence: 0.885277639166667

00:29:09.440 --> 00:29:11.960 And this included a PROTEOSOME inhibitor,
NOTE Confidence: 0.885277639166667

00:29:11.960 --> 00:29:15.080 an imid and an anti CD 38 antibody.
NOTE Confidence: 0.885277639166667

00:29:15.080 --> 00:29:17.103 And the three cohorts in this portion
NOTE Confidence: 0.885277639166667

00:29:17.103 --> 00:29:19.260 of the study that you see outlined
NOTE Confidence: 0.885277639166667

00:29:19.260 --> 00:29:21.394 here included a 0.4 milligram.
NOTE Confidence: 0.885277639166667

00:29:21.394 --> 00:29:24.429 4 kilogram weekly subcutaneous dosing
NOTE Confidence: 0.885277639166667

00:29:24.429 --> 00:29:26.220 and 122 patients enrolled in this.
NOTE Confidence: 0.885277639166667

00:29:26.220 --> 00:29:29.090 In this group 0.8 milligrams per kilogram
NOTE Confidence: 0.885277639166667

00:29:29.090 --> 00:29:31.570 every other week subcutaneous dosing
NOTE Confidence: 0.885277639166667

00:29:31.570 --> 00:29:33.316 where 109 patients were enrolled.
NOTE Confidence: 0.885277639166667

00:29:33.316 --> 00:29:35.450 And then a third group of patients
NOTE Confidence: 0.885277639166667

00:29:35.450 --> 00:29:37.478 who had received prior T cell
NOTE Confidence: 0.885277639166667

00:29:37.478 --> 00:29:38.492 redirection therapy and
NOTE Confidence: 0.818111631724138

00:29:38.556 --> 00:29:40.466 were administered either of the
NOTE Confidence: 0.818111631724138

00:29:40.466 --> 00:29:41.994 two mentioned dosing schedules.

NOTE Confidence: 0.818111631724138
00:29:42.000 --> 00:29:45.618 And the aim of this study was to assess
NOTE Confidence: 0.818111631724138
00:29:45.618 --> 00:29:48.708 efficacy and safety of this novel agent.
NOTE Confidence: 0.818111631724138
00:29:48.710 --> 00:29:50.942 And so the the table on the left here
NOTE Confidence: 0.818111631724138
00:29:50.942 --> 00:29:53.565 on the slide outline some of the key
NOTE Confidence: 0.818111631724138
00:29:53.565 --> 00:29:55.410 patient and disease characteristics from
NOTE Confidence: 0.818111631724138
00:29:55.410 --> 00:29:58.168 the phase two cohorts of this study.
NOTE Confidence: 0.818111631724138
00:29:58.170 --> 00:30:02.994 Median age was 67 and 8.4% of the 0.4
NOTE Confidence: 0.818111631724138
00:30:02.994 --> 00:30:05.856 milligram per kilogram group and 6.2% of
NOTE Confidence: 0.818111631724138
00:30:05.856 --> 00:30:07.974 the 0.8 kilogram milligram per kilogram
NOTE Confidence: 0.818111631724138
00:30:07.974 --> 00:30:10.330 group were black or African American.
NOTE Confidence: 0.818111631724138
00:30:10.330 --> 00:30:12.938 And as one would expect in a heavily
NOTE Confidence: 0.818111631724138
00:30:12.938 --> 00:30:14.508 pretreated population with an average
NOTE Confidence: 0.818111631724138
00:30:14.508 --> 00:30:17.104 of five prior lines of therapy high risk
NOTE Confidence: 0.818111631724138
00:30:17.104 --> 00:30:19.216 features including extramedullary disease.
NOTE Confidence: 0.818111631724138
00:30:19.220 --> 00:30:21.770 High risk cytogenetics and iss stage
NOTE Confidence: 0.818111631724138

00:30:21.770 --> 00:30:24.199 three disease were observed in about
NOTE Confidence: 0.818111631724138

00:30:24.199 --> 00:30:26.488 1/4 to 1/3 of patients as documented
NOTE Confidence: 0.818111631724138

00:30:26.488 --> 00:30:28.686 here in the table and approximately
NOTE Confidence: 0.818111631724138

00:30:28.686 --> 00:30:31.506 3/4 of the patients have triple had
NOTE Confidence: 0.818111631724138

00:30:31.506 --> 00:30:33.538 triple class refractory disease.
NOTE Confidence: 0.818111631724138

00:30:33.540 --> 00:30:35.815 However despite this population again
NOTE Confidence: 0.818111631724138

00:30:35.815 --> 00:30:39.000 with with high risk disease and there
NOTE Confidence: 0.818111631724138

00:30:39.000 --> 00:30:41.100 wasn't an impressive overall response
NOTE Confidence: 0.818111631724138

00:30:41.100 --> 00:30:44.439 rate as seen in the figure here on on the
NOTE Confidence: 0.818111631724138

00:30:44.439 --> 00:30:49.080 right at 74.1% and 73.1% in the two dosing.
NOTE Confidence: 0.818111631724138

00:30:49.080 --> 00:30:51.726 Groups and VGPR are better was
NOTE Confidence: 0.818111631724138

00:30:51.726 --> 00:30:53.841 achieved in approximately 60% of
NOTE Confidence: 0.818111631724138

00:30:53.841 --> 00:30:55.947 patients which also indicates a high
NOTE Confidence: 0.818111631724138

00:30:55.947 --> 00:30:58.048 depth of response with this agent.
NOTE Confidence: 0.818111631724138

00:30:58.050 --> 00:31:00.260 These responses were maintained across
NOTE Confidence: 0.818111631724138

00:31:00.260 --> 00:31:02.470 across subgroups except for those

NOTE Confidence: 0.818111631724138
00:31:02.533 --> 00:31:04.277 with Extramedullary disease where
NOTE Confidence: 0.818111631724138
00:31:04.277 --> 00:31:06.893 the overall response rate was reduced
NOTE Confidence: 0.818111631724138
00:31:06.954 --> 00:31:09.062 some at 50% and responses were rapid
NOTE Confidence: 0.818111631724138
00:31:09.062 --> 00:31:11.538 with the median time to response of
NOTE Confidence: 0.818111631724138
00:31:11.538 --> 00:31:13.650 a little over a month and a median
NOTE Confidence: 0.818111631724138
00:31:13.650 --> 00:31:16.046 time to best response of approximately
NOTE Confidence: 0.818111631724138
00:31:16.050 --> 00:31:18.150 2.5 months and thus far responses
NOTE Confidence: 0.818111631724138
00:31:18.150 --> 00:31:19.550 have also been durable.
NOTE Confidence: 0.818111631724138
00:31:19.550 --> 00:31:21.752 Of the median progression free survival
NOTE Confidence: 0.818111631724138
00:31:21.752 --> 00:31:24.674 at the time of presentation was 7.5
NOTE Confidence: 0.818111631724138
00:31:24.674 --> 00:31:27.026 months and 11.9 months in the 22 cohorts
NOTE Confidence: 0.818111631724138
00:31:27.026 --> 00:31:29.294 with a median duration of of response
NOTE Confidence: 0.818111631724138
00:31:29.294 --> 00:31:31.677 that was not reached in patients who
NOTE Confidence: 0.818111631724138
00:31:31.677 --> 00:31:33.765 had achieved a complete response or
NOTE Confidence: 0.818111631724138
00:31:33.765 --> 00:31:35.920 better and median overall survival was
NOTE Confidence: 0.818111631724138

00:31:35.920 --> 00:31:38.739 not reached for the study cohort to date.
NOTE Confidence: 0.818111631724138

00:31:38.740 --> 00:31:40.864 Importantly for the patients who had
NOTE Confidence: 0.818111631724138

00:31:40.864 --> 00:31:42.862 received prior T cell redirection
NOTE Confidence: 0.818111631724138

00:31:42.862 --> 00:31:44.905 therapy which included 70%,
NOTE Confidence: 0.818111631724138

00:31:44.905 --> 00:31:47.815 seventy .6% of patients who had
NOTE Confidence: 0.818111631724138

00:31:47.815 --> 00:31:50.181 received prior car T and 35.3%.
NOTE Confidence: 0.818111631724138

00:31:50.181 --> 00:31:52.467 Would have received prior by specific.
NOTE Confidence: 0.818111631724138

00:31:52.470 --> 00:31:54.595 The overall response rate was
NOTE Confidence: 0.818111631724138

00:31:54.595 --> 00:31:56.320 still high at 62.7%.
NOTE Confidence: 0.818111631724138

00:31:56.320 --> 00:31:59.470 Responses were higher in those that received
NOTE Confidence: 0.818111631724138

00:31:59.470 --> 00:32:02.509 prior car T compared to buy specifics,
NOTE Confidence: 0.818111631724138

00:32:02.510 --> 00:32:04.659 although the number of patients in in
NOTE Confidence: 0.818111631724138

00:32:04.659 --> 00:32:06.944 the study that received prior price by
NOTE Confidence: 0.818111631724138

00:32:06.944 --> 00:32:09.309 specifics was small with an end of 18.
NOTE Confidence: 0.855970994347826

00:32:12.000 --> 00:32:13.830 It's important to consider safety
NOTE Confidence: 0.855970994347826

00:32:13.830 --> 00:32:16.420 for this agent given its novel target

NOTE Confidence: 0.855970994347826
00:32:16.420 --> 00:32:18.155 as we discussed and fortunately
NOTE Confidence: 0.855970994347826
00:32:18.155 --> 00:32:20.400 as you can see outlined here,
NOTE Confidence: 0.855970994347826
00:32:20.400 --> 00:32:22.164 high grade adverse events were uncommon
NOTE Confidence: 0.855970994347826
00:32:22.164 --> 00:32:24.075 but when they were present they
NOTE Confidence: 0.855970994347826
00:32:24.075 --> 00:32:25.775 were mostly hematologic in nature.
NOTE Confidence: 0.855970994347826
00:32:25.780 --> 00:32:27.440 And with that being said,
NOTE Confidence: 0.855970994347826
00:32:27.440 --> 00:32:29.688 still there was less than 1/3 of patients
NOTE Confidence: 0.855970994347826
00:32:29.688 --> 00:32:31.548 that had high grade heme toxicities
NOTE Confidence: 0.855970994347826
00:32:31.548 --> 00:32:33.782 and most of the toxicity was limited
NOTE Confidence: 0.855970994347826
00:32:33.782 --> 00:32:35.994 to the first few cycles of treatment.
NOTE Confidence: 0.855970994347826
00:32:36.000 --> 00:32:37.760 High grade infections were also
NOTE Confidence: 0.855970994347826
00:32:37.760 --> 00:32:39.857 uncommon in this study and as
NOTE Confidence: 0.855970994347826
00:32:39.857 --> 00:32:41.726 you can see that included a low
NOTE Confidence: 0.855970994347826
00:32:41.726 --> 00:32:43.849 number of opportunistic infections.
NOTE Confidence: 0.855970994347826
00:32:43.850 --> 00:32:45.450 COVID infections occurred in
NOTE Confidence: 0.855970994347826

00:32:45.450 --> 00:32:47.168 approximately 10% of patients with
NOTE Confidence: 0.855970994347826

00:32:47.168 --> 00:32:49.310 only two deaths from COVID and actually
NOTE Confidence: 0.855970994347826

00:32:49.369 --> 00:32:51.322 0 deaths reported in the phase one
NOTE Confidence: 0.855970994347826

00:32:51.322 --> 00:32:53.199 portion that was published in the
NOTE Confidence: 0.855970994347826

00:32:53.199 --> 00:32:55.167 New England Journal back in December.
NOTE Confidence: 0.855970994347826

00:32:55.170 --> 00:32:55.892 As mentioned,
NOTE Confidence: 0.855970994347826

00:32:55.892 --> 00:32:58.419 rates of IVIG use were also relatively
NOTE Confidence: 0.855970994347826

00:32:58.419 --> 00:33:01.128 low with with less severe and this
NOTE Confidence: 0.855970994347826

00:33:01.128 --> 00:33:03.062 less severe infection signal that
NOTE Confidence: 0.855970994347826

00:33:03.062 --> 00:33:05.456 we're seeing in that with this agent
NOTE Confidence: 0.855970994347826

00:33:05.456 --> 00:33:08.160 is somewhat distinct from our anti
NOTE Confidence: 0.855970994347826

00:33:08.160 --> 00:33:11.190 BCM a targeted by specific antibodies
NOTE Confidence: 0.855970994347826

00:33:11.190 --> 00:33:13.780 that are now in utilization.
NOTE Confidence: 0.855970994347826

00:33:13.780 --> 00:33:16.366 The most common adverse events were
NOTE Confidence: 0.855970994347826

00:33:16.366 --> 00:33:18.360 cytokine release syndrome or CRS
NOTE Confidence: 0.855970994347826

00:33:18.360 --> 00:33:20.600 as well as altered taste.

NOTE Confidence: 0.855970994347826
00:33:20.600 --> 00:33:23.372 Or discuss Jia skin and nail
NOTE Confidence: 0.855970994347826
00:33:23.372 --> 00:33:26.399 related events as well and and the.
NOTE Confidence: 0.855970994347826
00:33:26.400 --> 00:33:28.962 The CRS events appear to be restricted
NOTE Confidence: 0.855970994347826
00:33:28.962 --> 00:33:31.431 largely to step up dosing and full
NOTE Confidence: 0.855970994347826
00:33:31.431 --> 00:33:33.736 first full dose with a median time
NOTE Confidence: 0.855970994347826
00:33:33.736 --> 00:33:36.020 to onset of two days immune effector
NOTE Confidence: 0.855970994347826
00:33:36.020 --> 00:33:37.760 cell associated neurotoxicity or
NOTE Confidence: 0.855970994347826
00:33:37.760 --> 00:33:40.479 what we refer to as icans occurred
NOTE Confidence: 0.855970994347826
00:33:40.479 --> 00:33:43.056 in about 10 to 11% of patients,
NOTE Confidence: 0.855970994347826
00:33:43.056 --> 00:33:46.254 but again we're mostly low grade.
NOTE Confidence: 0.855970994347826
00:33:46.260 --> 00:33:47.337 So in conclusion,
NOTE Confidence: 0.855970994347826
00:33:47.337 --> 00:33:50.973 tell Ketama B which is a a first in
NOTE Confidence: 0.855970994347826
00:33:50.973 --> 00:33:53.558 class by specific antibody again
NOTE Confidence: 0.855970994347826
00:33:53.558 --> 00:33:56.168 targeting novel GPRC 5D on myeloma
NOTE Confidence: 0.855970994347826
00:33:56.168 --> 00:33:57.736 cells demonstrated an impressive
NOTE Confidence: 0.855970994347826

00:33:57.736 --> 00:33:59.555 overall response rate of more than
NOTE Confidence: 0.855970994347826

00:33:59.555 --> 00:34:02.165 70% in patients with heavily pretreated
NOTE Confidence: 0.855970994347826

00:34:02.165 --> 00:34:04.057 relapsed and refractory myeloma.
NOTE Confidence: 0.855970994347826

00:34:04.060 --> 00:34:05.962 And high overall response rates were
NOTE Confidence: 0.855970994347826

00:34:05.962 --> 00:34:08.302 also seen in those who had received
NOTE Confidence: 0.855970994347826

00:34:08.302 --> 00:34:09.977 prior T cell redirection therapy
NOTE Confidence: 0.855970994347826

00:34:09.977 --> 00:34:12.154 which is an important cohort to
NOTE Confidence: 0.855970994347826

00:34:12.154 --> 00:34:14.039 learn more about responses have
NOTE Confidence: 0.855970994347826

00:34:14.039 --> 00:34:15.889 been durable and the agent.
NOTE Confidence: 0.855970994347826

00:34:15.890 --> 00:34:17.785 Because generally been overall well
NOTE Confidence: 0.855970994347826

00:34:17.785 --> 00:34:20.111 tolerated with CRS that seems to
NOTE Confidence: 0.855970994347826

00:34:20.111 --> 00:34:21.956 be manageable and fewer infections.
NOTE Confidence: 0.855970994347826

00:34:21.960 --> 00:34:24.258 Although it does have unique safety
NOTE Confidence: 0.855970994347826

00:34:24.258 --> 00:34:26.182 profile and those include things
NOTE Confidence: 0.855970994347826

00:34:26.182 --> 00:34:28.108 like skin and nail related events
NOTE Confidence: 0.855970994347826

00:34:28.108 --> 00:34:30.930 as well as taste alteration or dysia

NOTE Confidence: 0.855970994347826
00:34:30.930 --> 00:34:32.277 as previously mentioned.
NOTE Confidence: 0.855970994347826
00:34:32.280 --> 00:34:33.935 Although these were generally managed
NOTE Confidence: 0.855970994347826
00:34:33.935 --> 00:34:35.899 with supportive care and there was
NOTE Confidence: 0.855970994347826
00:34:35.899 --> 00:34:37.417 a low overall rate of discontinuation
NOTE Confidence: 0.855970994347826
00:34:37.417 --> 00:34:39.515 due to the adverse events and and
NOTE Confidence: 0.855970994347826
00:34:39.515 --> 00:34:41.120 therefore there are additional studies
NOTE Confidence: 0.855970994347826
00:34:41.120 --> 00:34:43.208 that are now ongoing to looking at
NOTE Confidence: 0.855970994347826
00:34:43.208 --> 00:34:45.978 the look at talked amab both in combination.
NOTE Confidence: 0.855970994347826
00:34:45.980 --> 00:34:49.058 In combination with a variety of
NOTE Confidence: 0.855970994347826
00:34:49.058 --> 00:34:51.110 different anti myeloma agents.
NOTE Confidence: 0.855970994347826
00:34:51.110 --> 00:34:52.946 And so next I want to briefly share
NOTE Confidence: 0.855970994347826
00:34:52.946 --> 00:34:54.670 with you the following abstract.
NOTE Confidence: 0.855970994347826
00:34:54.670 --> 00:34:56.992 This was presented by Doctor Jesus
NOTE Confidence: 0.855970994347826
00:34:56.992 --> 00:35:00.191 Berdeja and this is now a novel car
NOTE Confidence: 0.855970994347826
00:35:00.191 --> 00:35:02.161 T cell therapy therapy that's
NOTE Confidence: 0.855970994347826

00:35:02.161 --> 00:35:03.922 targeting GPRC 5D and and this has
NOTE Confidence: 0.855970994347826

00:35:03.922 --> 00:35:06.124 a this car T construct as seen in
NOTE Confidence: 0.855970994347826

00:35:06.124 --> 00:35:07.966 the figure here on the right.
NOTE Confidence: 0.855970994347826

00:35:07.970 --> 00:35:10.357 And this data came from a phase
NOTE Confidence: 0.855970994347826

00:35:10.357 --> 00:35:12.170 one multicenter open label study
NOTE Confidence: 0.855970994347826

00:35:12.170 --> 00:35:14.246 and the data was presented on
NOTE Confidence: 0.855970994347826

00:35:14.246 --> 00:35:15.630 33 patients enrolled in
NOTE Confidence: 0.823225243181818

00:35:15.703 --> 00:35:18.629 the part a dose escalation cohort eligible
NOTE Confidence: 0.823225243181818

00:35:18.629 --> 00:35:21.199 patients had relapsed refractory myeloma.
NOTE Confidence: 0.823225243181818

00:35:21.200 --> 00:35:23.888 With three or more prior lines of therapy
NOTE Confidence: 0.823225243181818

00:35:23.888 --> 00:35:26.279 and prior BCMA therapy was allowed,
NOTE Confidence: 0.823225243181818

00:35:26.280 --> 00:35:29.094 there were five dose levels that were
NOTE Confidence: 0.823225243181818

00:35:29.094 --> 00:35:31.402 tested from ranging from 25 to 450
NOTE Confidence: 0.823225243181818

00:35:31.402 --> 00:35:33.978 million car T cells and thus far the
NOTE Confidence: 0.823225243181818

00:35:33.978 --> 00:35:36.579 state the overall safety and efficacy
NOTE Confidence: 0.823225243181818

00:35:36.579 --> 00:35:39.560 profile have profiles have been favorable.

NOTE Confidence: 0.823225243181818
00:35:39.560 --> 00:35:41.972 Treatment emergent adverse events were seen
NOTE Confidence: 0.823225243181818
00:35:41.972 --> 00:35:46.360 in close to 88% of patients and 73% of of
NOTE Confidence: 0.823225243181818
00:35:46.360 --> 00:35:49.920 patients had grade 3 or 4 adverse events.
NOTE Confidence: 0.823225243181818
00:35:49.920 --> 00:35:53.140 And in comparison to Cal talked tamag,
NOTE Confidence: 0.823225243181818
00:35:53.140 --> 00:35:54.912 hematologic adverse events and
NOTE Confidence: 0.823225243181818
00:35:54.912 --> 00:35:56.241 and particularly neutropenia
NOTE Confidence: 0.823225243181818
00:35:56.241 --> 00:35:57.127 and thrombocytopenia.
NOTE Confidence: 0.823225243181818
00:35:57.130 --> 00:35:59.284 Thrombocytopenia seemed to be more more
NOTE Confidence: 0.823225243181818
00:35:59.284 --> 00:36:02.285 common with a a dose limiting toxicity
NOTE Confidence: 0.823225243181818
00:36:02.285 --> 00:36:05.267 of prolonged grade 4 neutropenia and
NOTE Confidence: 0.823225243181818
00:36:05.267 --> 00:36:06.880 thrombocytopenia in two patients.
NOTE Confidence: 0.823225243181818
00:36:06.880 --> 00:36:09.238 Again CRS was the most common
NOTE Confidence: 0.823225243181818
00:36:09.238 --> 00:36:10.024 non hematologic.
NOTE Confidence: 0.823225243181818
00:36:10.030 --> 00:36:14.250 Reverse advent at 63.6% and the median time
NOTE Confidence: 0.823225243181818
00:36:14.250 --> 00:36:17.570 to onset with this cartee was three days.
NOTE Confidence: 0.823225243181818

00:36:17.570 --> 00:36:20.097 Although grade three and four CRS events
NOTE Confidence: 0.823225243181818

00:36:20.097 --> 00:36:22.394 were only observed in 6% of patients.
NOTE Confidence: 0.823225243181818

00:36:22.394 --> 00:36:24.926 I cans was infrequent with only two
NOTE Confidence: 0.823225243181818

00:36:24.926 --> 00:36:27.147 two patients and was reversible
NOTE Confidence: 0.823225243181818

00:36:27.147 --> 00:36:28.449 in both instances.
NOTE Confidence: 0.823225243181818

00:36:28.450 --> 00:36:30.570 Instances with steroid treatment,
NOTE Confidence: 0.823225243181818

00:36:30.570 --> 00:36:33.220 again because of the GPR,
NOTE Confidence: 0.823225243181818

00:36:33.220 --> 00:36:36.900 the unique target that that this car T
NOTE Confidence: 0.823225243181818

00:36:36.900 --> 00:36:40.036 targets there were skin and nail related.
NOTE Confidence: 0.823225243181818

00:36:40.040 --> 00:36:42.798 Adverse events as well as taste alterations,
NOTE Confidence: 0.823225243181818

00:36:42.800 --> 00:36:45.232 but these seem to be less common than
NOTE Confidence: 0.823225243181818

00:36:45.232 --> 00:36:47.357 talked amab and all were low grade
NOTE Confidence: 0.823225243181818

00:36:47.357 --> 00:36:49.251 and the majority did not require
NOTE Confidence: 0.823225243181818

00:36:49.251 --> 00:36:50.739 any sort of treatment.
NOTE Confidence: 0.823225243181818

00:36:50.740 --> 00:36:52.888 The maximum tolerated dose has not
NOTE Confidence: 0.823225243181818

00:36:52.888 --> 00:36:55.388 yet been exceeded in this study and

NOTE Confidence: 0.823225243181818
00:36:55.388 --> 00:36:57.380 there have been no deaths thought
NOTE Confidence: 0.823225243181818
00:36:57.380 --> 00:36:59.738 to be related to study treatment.
NOTE Confidence: 0.823225243181818
00:36:59.740 --> 00:37:00.236 Importantly,
NOTE Confidence: 0.823225243181818
00:37:00.236 --> 00:37:03.708 the overall response rate of the total
NOTE Confidence: 0.823225243181818
00:37:03.708 --> 00:37:07.302 cohort what was high at 89.5% with a CR
NOTE Confidence: 0.823225243181818
00:37:07.302 --> 00:37:10.155 rate a complete response rate of 47.4.
NOTE Confidence: 0.823225243181818
00:37:10.155 --> 00:37:12.405 Percent and there were four patients
NOTE Confidence: 0.823225243181818
00:37:12.405 --> 00:37:14.208 that were evaluated for minimal
NOTE Confidence: 0.823225243181818
00:37:14.208 --> 00:37:16.056 residual disease or MRD and all
NOTE Confidence: 0.823225243181818
00:37:16.056 --> 00:37:18.190 four of those were MRD negative.
NOTE Confidence: 0.823225243181818
00:37:18.190 --> 00:37:19.579 So in conclusion,
NOTE Confidence: 0.823225243181818
00:37:19.579 --> 00:37:21.894 responses with this novel cartee
NOTE Confidence: 0.823225243181818
00:37:21.894 --> 00:37:24.292 seem durable and and seem to
NOTE Confidence: 0.823225243181818
00:37:24.292 --> 00:37:25.688 also deepen over time,
NOTE Confidence: 0.823225243181818
00:37:25.690 --> 00:37:27.130 making this a promising
NOTE Confidence: 0.823225243181818

00:37:27.130 --> 00:37:28.210 treatment moving forward,
NOTE Confidence: 0.823225243181818

00:37:28.210 --> 00:37:30.382 including in those patients that are
NOTE Confidence: 0.823225243181818

00:37:30.382 --> 00:37:32.629 already exposed to BCM a treatment.
NOTE Confidence: 0.810628541333333

00:37:34.840 --> 00:37:37.493 The the next abstract that I will
NOTE Confidence: 0.810628541333333

00:37:37.493 --> 00:37:39.377 present was discussed by Doctor
NOTE Confidence: 0.810628541333333

00:37:39.377 --> 00:37:41.736 Susan Trudell and it looked at 1
NOTE Confidence: 0.810628541333333

00:37:41.736 --> 00:37:43.871 cohort in a safety and efficacy
NOTE Confidence: 0.810628541333333

00:37:43.871 --> 00:37:45.938 trial of savasta amab and SAVASA.
NOTE Confidence: 0.810628541333333

00:37:45.938 --> 00:37:47.966 Amab is a bispecific antibody seen
NOTE Confidence: 0.810628541333333

00:37:47.966 --> 00:37:50.542 here on the right that targets yet
NOTE Confidence: 0.810628541333333

00:37:50.542 --> 00:37:52.252 another new myeloma antigen known
NOTE Confidence: 0.810628541333333

00:37:52.252 --> 00:37:55.044 known as FC RH Five which again is
NOTE Confidence: 0.810628541333333

00:37:55.044 --> 00:37:57.204 exclusively expressed in B cell lineage
NOTE Confidence: 0.810628541333333

00:37:57.204 --> 00:37:59.725 and is thought to be near ubiquitous
NOTE Confidence: 0.810628541333333

00:37:59.725 --> 00:38:02.810 on myeloma cells and at ASH in 2021
NOTE Confidence: 0.810628541333333

00:38:02.810 --> 00:38:05.060 there was initial data presented.

NOTE Confidence: 0.810628541333333
00:38:05.060 --> 00:38:07.428 On the phase one dose finding study of
NOTE Confidence: 0.810628541333333
00:38:07.428 --> 00:38:09.526 savasta mab and revealed a favorable
NOTE Confidence: 0.810628541333333
00:38:09.526 --> 00:38:11.692 efficacy and safety profile in those
NOTE Confidence: 0.810628541333333
00:38:11.756 --> 00:38:13.865 patients with heavily pretreated
NOTE Confidence: 0.810628541333333
00:38:13.865 --> 00:38:16.045 relapsed and refractory myeloma.
NOTE Confidence: 0.810628541333333
00:38:16.050 --> 00:38:17.582 This year's abstract reviews
NOTE Confidence: 0.810628541333333
00:38:17.582 --> 00:38:20.250 reviewed a cohort in this study who
NOTE Confidence: 0.810628541333333
00:38:20.250 --> 00:38:22.650 received a single dose of the IL 6
NOTE Confidence: 0.810628541333333
00:38:22.650 --> 00:38:24.550 receptor blocker to Solus amount
NOTE Confidence: 0.810628541333333
00:38:24.550 --> 00:38:26.465 at 8 milligrams per kilograms.
NOTE Confidence: 0.810628541333333
00:38:26.470 --> 00:38:28.494 And and this was given 2 hours prior
NOTE Confidence: 0.810628541333333
00:38:28.494 --> 00:38:30.703 to the first of Austin maps step up
NOTE Confidence: 0.810628541333333
00:38:30.703 --> 00:38:33.450 dose which is 3.6 milligram and these
NOTE Confidence: 0.810628541333333
00:38:33.450 --> 00:38:35.850 patients were then compared retrospectively.
NOTE Confidence: 0.810628541333333
00:38:35.850 --> 00:38:37.890 To a previously enrolled group who
NOTE Confidence: 0.810628541333333

00:38:37.890 --> 00:38:39.930 did not receive tocilizumab and the
NOTE Confidence: 0.810628541333333

00:38:39.930 --> 00:38:41.802 objective which was based on preclinical
NOTE Confidence: 0.810628541333333

00:38:41.802 --> 00:38:43.893 data was to determine whether there's
NOTE Confidence: 0.810628541333333

00:38:43.893 --> 00:38:45.999 this would reduce the the frequency
NOTE Confidence: 0.810628541333333

00:38:46.000 --> 00:38:47.986 of cytokine release syndrome or CRS
NOTE Confidence: 0.810628541333333

00:38:47.986 --> 00:38:50.197 which as we've discussed now in several
NOTE Confidence: 0.810628541333333

00:38:50.197 --> 00:38:52.129 abstracts is one of the most common
NOTE Confidence: 0.810628541333333

00:38:52.185 --> 00:38:54.060 adverse event with bispecific antibody
NOTE Confidence: 0.810628541333333

00:38:54.060 --> 00:38:56.387 treatment and it's thought to be
NOTE Confidence: 0.810628541333333

00:38:56.387 --> 00:38:59.516 mediated by IL six and other cytokines.
NOTE Confidence: 0.810628541333333

00:38:59.520 --> 00:39:01.833 And as you can see here on the the
NOTE Confidence: 0.810628541333333

00:39:01.833 --> 00:39:03.816 bottom savasa amab is its administered
NOTE Confidence: 0.810628541333333

00:39:03.816 --> 00:39:05.860 with a single step up dose.
NOTE Confidence: 0.810628541333333

00:39:05.860 --> 00:39:07.780 Initially at 3.6 milligrams and then
NOTE Confidence: 0.810628541333333

00:39:07.780 --> 00:39:10.149 to a target dose of 90 milligrams,
NOTE Confidence: 0.810628541333333

00:39:10.150 --> 00:39:12.046 and it's given intravenously

NOTE Confidence: 0.810628541333333
00:39:12.046 --> 00:39:13.468 every three weeks.
NOTE Confidence: 0.84287700875
00:39:16.460 --> 00:39:19.729 So 31 patients were enrolled in the
NOTE Confidence: 0.84287700875
00:39:19.729 --> 00:39:21.716 total amount pretreatment arm with
NOTE Confidence: 0.84287700875
00:39:21.716 --> 00:39:24.304 44 patients in the comparator arm and
NOTE Confidence: 0.84287700875
00:39:24.304 --> 00:39:26.509 in both groups as you can see in the
NOTE Confidence: 0.84287700875
00:39:26.570 --> 00:39:29.314 table here on the left included heavily
NOTE Confidence: 0.84287700875
00:39:29.314 --> 00:39:31.504 pretreated patients with a median time,
NOTE Confidence: 0.84287700875
00:39:31.504 --> 00:39:33.820 excuse me, a median line of therapies
NOTE Confidence: 0.84287700875
00:39:33.820 --> 00:39:35.924 being four and six respectively with
NOTE Confidence: 0.84287700875
00:39:35.924 --> 00:39:37.959 fairly similar patient and disease
NOTE Confidence: 0.84287700875
00:39:37.959 --> 00:39:39.916 characteristics except for those that
NOTE Confidence: 0.84287700875
00:39:39.916 --> 00:39:42.084 I've highlighted for you here on the in
NOTE Confidence: 0.84287700875
00:39:42.084 --> 00:39:44.349 the table on the left and as you can see
NOTE Confidence: 0.84287700875
00:39:44.349 --> 00:39:46.567 the tocilizumab pretreatment group did.
NOTE Confidence: 0.84287700875
00:39:46.570 --> 00:39:47.906 Have somewhat less extramedullary
NOTE Confidence: 0.84287700875

00:39:47.906 --> 00:39:49.910 disease as well as less penta,
NOTE Confidence: 0.84287700875

00:39:49.910 --> 00:39:52.538 refractory penta drug refractory disease and
NOTE Confidence: 0.84287700875

00:39:52.538 --> 00:39:55.690 fewer patients in the tocilizumab are arm.
NOTE Confidence: 0.84287700875

00:39:55.690 --> 00:39:59.029 Had received prior anti BCM cell therapy
NOTE Confidence: 0.84287700875

00:39:59.030 --> 00:40:00.938 and the most commonly observed adverse
NOTE Confidence: 0.84287700875

00:40:00.938 --> 00:40:03.170 events in both groups were neutropenia,
NOTE Confidence: 0.84287700875

00:40:03.170 --> 00:40:05.606 anemia, thrombocytopenia and CRS and of
NOTE Confidence: 0.84287700875

00:40:05.606 --> 00:40:08.517 no neutropenia which is a known side
NOTE Confidence: 0.84287700875

00:40:08.517 --> 00:40:10.547 effect of tocilizumab with significantly
NOTE Confidence: 0.84287700875

00:40:10.547 --> 00:40:13.299 higher in the Tosi pre treatment group,
NOTE Confidence: 0.84287700875

00:40:13.300 --> 00:40:15.156 but was said by the authors to be
NOTE Confidence: 0.84287700875

00:40:15.156 --> 00:40:16.788 reversible and manageable with growth.
NOTE Confidence: 0.84287700875

00:40:16.790 --> 00:40:19.177 Doctor um when appropriate and this did
NOTE Confidence: 0.84287700875

00:40:19.177 --> 00:40:22.220 not lead to Savasta Amab discontinuation.
NOTE Confidence: 0.84287700875

00:40:22.220 --> 00:40:24.110 The infection rate was also reportedly
NOTE Confidence: 0.84287700875

00:40:24.110 --> 00:40:25.620 higher than the comparator arm,

NOTE Confidence: 0.84287700875

00:40:25.620 --> 00:40:27.365 although compared to other cohorts

NOTE Confidence: 0.84287700875

00:40:27.365 --> 00:40:29.896 in the study there was a similar

NOTE Confidence: 0.84287700875

00:40:29.896 --> 00:40:32.423 infection rate and grade three grade 3

NOTE Confidence: 0.84287700875

00:40:32.423 --> 00:40:34.535 infections also occurred at a similar

NOTE Confidence: 0.84287700875

00:40:34.535 --> 00:40:36.497 rate between these two study groups.

NOTE Confidence: 0.84287700875

00:40:36.497 --> 00:40:38.713 And as you can see in the figure

NOTE Confidence: 0.84287700875

00:40:38.713 --> 00:40:39.859 here on the right,

NOTE Confidence: 0.84287700875

00:40:39.860 --> 00:40:42.128 the overall rate of CRS was

NOTE Confidence: 0.84287700875

00:40:42.128 --> 00:40:44.466 significantly lower in the Tosi Pre

NOTE Confidence: 0.84287700875

00:40:44.466 --> 00:40:46.048 treatment group at 38.7%.

NOTE Confidence: 0.84287700875

00:40:46.048 --> 00:40:48.736 Compared to the non Tosi group

NOTE Confidence: 0.84287700875

00:40:48.736 --> 00:40:51.158 at 90.9% CRS was limited to grade

NOTE Confidence: 0.84287700875

00:40:51.158 --> 00:40:53.619 one and Grade 2 events in both,

NOTE Confidence: 0.84287700875

00:40:53.620 --> 00:40:55.510 in both cohorts in both groups with

NOTE Confidence: 0.84287700875

00:40:55.510 --> 00:40:57.439 the median time to onset of one day.

NOTE Confidence: 0.84287700875

00:40:57.440 --> 00:40:59.906 And the beneficial effects of Tosi
NOTE Confidence: 0.84287700875

00:40:59.910 --> 00:41:02.712 on CRS were continued with subsequent
NOTE Confidence: 0.84287700875

00:41:02.712 --> 00:41:04.580 doses in cycle one.
NOTE Confidence: 0.84287700875

00:41:04.580 --> 00:41:07.460 In the tocilizumab pretreatment arm.
NOTE Confidence: 0.84287700875

00:41:07.460 --> 00:41:09.844 I can't was seen in frequently in both
NOTE Confidence: 0.84287700875

00:41:09.844 --> 00:41:11.464 groups occurred in only two patients
NOTE Confidence: 0.84287700875

00:41:11.464 --> 00:41:13.939 in the Tosi arm and six patients in the
NOTE Confidence: 0.84287700875

00:41:13.939 --> 00:41:15.870 non-toxic arm and interestingly the
NOTE Confidence: 0.84287700875

00:41:15.870 --> 00:41:18.020 authors demonstrated in the toasty.
NOTE Confidence: 0.84287700875

00:41:18.020 --> 00:41:21.030 Pretreatment arm that after the 1st
NOTE Confidence: 0.84287700875

00:41:21.030 --> 00:41:23.330 3.6 milligrams of fastmac dose,
NOTE Confidence: 0.84287700875

00:41:23.330 --> 00:41:25.430 there were higher peak levels of IL
NOTE Confidence: 0.84287700875

00:41:25.430 --> 00:41:27.749 6 which were hypothesized to be due
NOTE Confidence: 0.84287700875

00:41:27.749 --> 00:41:30.237 to inhibition of IL 6 clearance by
NOTE Confidence: 0.84287700875

00:41:30.237 --> 00:41:31.029 the tocilizumab.
NOTE Confidence: 0.84287700875

00:41:31.030 --> 00:41:31.388 However,

NOTE Confidence: 0.84287700875

00:41:31.388 --> 00:41:33.178 there was also near complete

NOTE Confidence: 0.84287700875

00:41:33.178 --> 00:41:35.348 suppression of CRP which is produced

NOTE Confidence: 0.84287700875

00:41:35.348 --> 00:41:37.728 by IL 6 receptor binding and thereby

NOTE Confidence: 0.84287700875

00:41:37.728 --> 00:41:39.402 suggesting that there was effective

NOTE Confidence: 0.84287700875

00:41:39.402 --> 00:41:42.034 blockade or blockage of the IL 6

NOTE Confidence: 0.84287700875

00:41:42.034 --> 00:41:44.930 inflammatory signal signaling pathway,

NOTE Confidence: 0.84287700875

00:41:44.930 --> 00:41:46.790 also importantly pretreatment

NOTE Confidence: 0.84287700875

00:41:46.790 --> 00:41:48.030 with tocilizumab.

NOTE Confidence: 0.84287700875

00:41:48.030 --> 00:41:50.820 Did not appear to negatively impact

NOTE Confidence: 0.84287700875

00:41:50.820 --> 00:41:53.060 clinical response rates with an

NOTE Confidence: 0.84287700875

00:41:53.060 --> 00:41:55.530 overall response rate rate of 54.8%

NOTE Confidence: 0.84287700875

00:41:55.530 --> 00:41:57.750 and a very good partial response

NOTE Confidence: 0.84287700875

00:41:57.750 --> 00:42:00.666 or a VGR or better rate of 32.3%

NOTE Confidence: 0.84287700875

00:42:00.666 --> 00:42:02.596 observed in the Tosi group.

NOTE Confidence: 0.84287700875

00:42:02.600 --> 00:42:04.868 And that was compared to an overall

NOTE Confidence: 0.84287700875

00:42:04.868 --> 00:42:07.535 response rate of 37.2% and VG,
NOTE Confidence: 0.84287700875

00:42:07.535 --> 00:42:11.251 VG PR or better of 25.5% in the
NOTE Confidence: 0.84287700875

00:42:11.251 --> 00:42:13.033 the non-toxic arm and median time
NOTE Confidence: 0.84287700875

00:42:13.033 --> 00:42:15.436 to best response as well as median
NOTE Confidence: 0.84287700875

00:42:15.436 --> 00:42:17.234 duration of response was similar
NOTE Confidence: 0.84287700875

00:42:17.234 --> 00:42:18.738 between the two groups.
NOTE Confidence: 0.84287700875

00:42:18.740 --> 00:42:19.886 So in conclusion,
NOTE Confidence: 0.84287700875

00:42:19.886 --> 00:42:21.414 pretreatment with a single
NOTE Confidence: 0.84287700875

00:42:21.414 --> 00:42:22.560 dose of tocilizumab
NOTE Confidence: 0.7604757118

00:42:22.626 --> 00:42:24.918 prior to the initiation of savasa
NOTE Confidence: 0.7604757118

00:42:24.918 --> 00:42:26.846 amab significantly reduced the the
NOTE Confidence: 0.7604757118

00:42:26.846 --> 00:42:29.184 the rate of CRS in patients with
NOTE Confidence: 0.7604757118

00:42:29.184 --> 00:42:30.594 relapsed refractory myeloma likely
NOTE Confidence: 0.7604757118

00:42:30.594 --> 00:42:32.429 thought to be through suppression
NOTE Confidence: 0.7604757118

00:42:32.429 --> 00:42:34.860 of the IL 6 signaling pathway,
NOTE Confidence: 0.7604757118

00:42:34.860 --> 00:42:37.212 but did not seem to negatively impact the

NOTE Confidence: 0.7604757118

00:42:37.212 --> 00:42:39.380 anti myeloma activity of this Asia agent.

NOTE Confidence: 0.7604757118

00:42:39.380 --> 00:42:41.662 And so the authors noted that two

NOTE Confidence: 0.7604757118

00:42:41.662 --> 00:42:43.765 salesman may may play an important

NOTE Confidence: 0.7604757118

00:42:43.765 --> 00:42:46.229 future role in CRS mitigation as pre

NOTE Confidence: 0.7604757118

00:42:46.299 --> 00:42:48.910 dosing and may potentially help us move.

NOTE Confidence: 0.7604757118

00:42:48.910 --> 00:42:50.558 By specific treatment to

NOTE Confidence: 0.7604757118

00:42:50.558 --> 00:42:51.794 the outpatient setting.

NOTE Confidence: 0.7462215285

00:42:54.330 --> 00:42:57.096 The the next abstract was presented

NOTE Confidence: 0.7462215285

00:42:57.096 --> 00:42:59.735 by Doctor Paul Richardson and this

NOTE Confidence: 0.7462215285

00:42:59.735 --> 00:43:01.889 was on amazing amide or what?

NOTE Confidence: 0.7462215285

00:43:01.890 --> 00:43:03.445 What's referred to as Messi

NOTE Confidence: 0.7462215285

00:43:03.445 --> 00:43:05.989 and Messi is a a potent novel.

NOTE Confidence: 0.7462215285

00:43:05.990 --> 00:43:07.929 Sarah Blunt Eli Gaze modulator or what

NOTE Confidence: 0.7462215285

00:43:07.929 --> 00:43:10.718 we know as a cell mod and this was looked

NOTE Confidence: 0.7462215285

00:43:10.718 --> 00:43:12.670 at in combination with dexamethasone.

NOTE Confidence: 0.7462215285

00:43:12.670 --> 00:43:15.198 In this abstract Messi is an oral agent
NOTE Confidence: 0.7462215285

00:43:15.198 --> 00:43:18.169 and as could be seen in the figure here,
NOTE Confidence: 0.7462215285

00:43:18.170 --> 00:43:20.078 it binds and activates Sarah blown
NOTE Confidence: 0.7462215285

00:43:20.078 --> 00:43:22.558 and it leads to what happens is
NOTE Confidence: 0.7462215285

00:43:22.558 --> 00:43:24.463 it leads to maximal degradation.
NOTE Confidence: 0.7462215285

00:43:24.470 --> 00:43:26.126 Of important transcription factors
NOTE Confidence: 0.7462215285

00:43:26.126 --> 00:43:29.036 and that includes ICAROS and ilos that
NOTE Confidence: 0.7462215285

00:43:29.036 --> 00:43:31.178 are both really important in myeloma
NOTE Confidence: 0.7462215285

00:43:31.180 --> 00:43:32.659 pathophysiology and pathobiology.
NOTE Confidence: 0.7462215285

00:43:32.659 --> 00:43:35.617 And this results in enhanced myeloma
NOTE Confidence: 0.7462215285

00:43:35.617 --> 00:43:37.949 cell killing and immune stimulatory
NOTE Confidence: 0.7462215285

00:43:37.949 --> 00:43:40.595 activity when compared to our common
NOTE Confidence: 0.7462215285

00:43:40.663 --> 00:43:43.558 immunomodulatory drugs such as Lenalidomide.
NOTE Confidence: 0.7462215285

00:43:43.560 --> 00:43:45.534 And in this phase one two trial,
NOTE Confidence: 0.7462215285

00:43:45.540 --> 00:43:47.994 Messi was evaluated alone and in
NOTE Confidence: 0.7462215285

00:43:47.994 --> 00:43:49.630 combination with dexamethasone and

NOTE Confidence: 0.7462215285

00:43:49.697 --> 00:43:51.785 the recommended phase two dose for

NOTE Confidence: 0.7462215285

00:43:51.785 --> 00:43:54.107 for Messi was selected at 1 milligram

NOTE Confidence: 0.7462215285

00:43:54.107 --> 00:43:55.259 daily for 21 days.

NOTE Confidence: 0.7462215285

00:43:55.260 --> 00:43:58.445 Out of a 28 day cycle with a notable

NOTE Confidence: 0.7462215285

00:43:58.445 --> 00:44:00.515 overall response rate in the phase

NOTE Confidence: 0.7462215285

00:44:00.515 --> 00:44:04.154 one portion of 54.5% and to be

NOTE Confidence: 0.7462215285

00:44:04.154 --> 00:44:05.930 eligible for the phase two dose

NOTE Confidence: 0.7462215285

00:44:05.998 --> 00:44:08.038 expansion portion of the study that

NOTE Confidence: 0.7462215285

00:44:08.038 --> 00:44:10.349 was reported in in this abstract,

NOTE Confidence: 0.7462215285

00:44:10.350 --> 00:44:12.438 patients had to be relapsed refractory

NOTE Confidence: 0.7462215285

00:44:12.438 --> 00:44:15.197 and have had received three or more prior

NOTE Confidence: 0.7462215285

00:44:15.197 --> 00:44:17.147 lines of treatment and be refractory

NOTE Confidence: 0.7462215285

00:44:17.212 --> 00:44:19.480 to at least one immunomodulatory agent.

NOTE Confidence: 0.7462215285

00:44:19.480 --> 00:44:22.012 Again prior exposure to CMA therapy

NOTE Confidence: 0.7462215285

00:44:22.012 --> 00:44:24.141 was allowed and dexamethasone was

NOTE Confidence: 0.7462215285

00:44:24.141 --> 00:44:26.367 administered at 20 to 40 milligrams.
NOTE Confidence: 0.7462215285

00:44:26.370 --> 00:44:29.765 Dependent on age in combination with Mezzi,
NOTE Confidence: 0.7462215285

00:44:29.770 --> 00:44:31.870 the main objectives of the study
NOTE Confidence: 0.7462215285

00:44:31.870 --> 00:44:33.270 included advocacy and safety
NOTE Confidence: 0.7462215285

00:44:33.328 --> 00:44:34.820 of this novel combination.
NOTE Confidence: 0.769961027307693

00:44:37.160 --> 00:44:39.617 So 101 patients were included in the
NOTE Confidence: 0.769961027307693

00:44:39.617 --> 00:44:42.806 MEZZI plus DEX cohort and they're patient
NOTE Confidence: 0.769961027307693

00:44:42.806 --> 00:44:44.870 and disease disease characteristics
NOTE Confidence: 0.769961027307693

00:44:44.870 --> 00:44:47.700 are outlined in the table on the left.
NOTE Confidence: 0.769961027307693

00:44:47.700 --> 00:44:50.852 Median age as expected was 67 years and
NOTE Confidence: 0.769961027307693

00:44:50.852 --> 00:44:53.373 these were heavily pretreated patients
NOTE Confidence: 0.769961027307693

00:44:53.373 --> 00:44:56.679 with a median time since initial
NOTE Confidence: 0.769961027307693

00:44:56.679 --> 00:44:59.024 diagnosis of myeloma of 7.44 years,
NOTE Confidence: 0.769961027307693

00:44:59.024 --> 00:45:01.418 a median of 6 lines of prior
NOTE Confidence: 0.769961027307693

00:45:01.418 --> 00:45:03.320 treatment and 100% of patients
NOTE Confidence: 0.769961027307693

00:45:03.320 --> 00:45:05.200 were triple class refractory.

NOTE Confidence: 0.769961027307693
00:45:05.200 --> 00:45:06.472 There were only approximately
NOTE Confidence: 0.769961027307693
00:45:06.472 --> 00:45:08.401 20% of patients with.
NOTE Confidence: 0.769961027307693
00:45:08.401 --> 00:45:11.023 Stage three disease although 39.6
NOTE Confidence: 0.769961027307693
00:45:11.023 --> 00:45:13.388 had extramedullary disease and this
NOTE Confidence: 0.769961027307693
00:45:13.388 --> 00:45:16.307 included in in their study soft
NOTE Confidence: 0.769961027307693
00:45:16.307 --> 00:45:18.199 tissue bone related plasmacytoma
NOTE Confidence: 0.769961027307693
00:45:18.199 --> 00:45:21.841 in in addition to true soft tissue
NOTE Confidence: 0.769961027307693
00:45:21.841 --> 00:45:24.666 extramedullary disease and 36.6% of
NOTE Confidence: 0.769961027307693
00:45:24.666 --> 00:45:27.556 patients had high risk cytogenetics
NOTE Confidence: 0.769961027307693
00:45:27.560 --> 00:45:30.140 29.7% of patients had received prior
NOTE Confidence: 0.769961027307693
00:45:30.140 --> 00:45:32.709 anti BCMH treatment mostly in the
NOTE Confidence: 0.769961027307693
00:45:32.709 --> 00:45:34.659 form of antibody drug conjugates.
NOTE Confidence: 0.769961027307693
00:45:34.660 --> 00:45:37.156 And in terms of clinical activity,
NOTE Confidence: 0.769961027307693
00:45:37.160 --> 00:45:38.203 as you can see on the figure
NOTE Confidence: 0.769961027307693
00:45:38.203 --> 00:45:38.920 here on the right,
NOTE Confidence: 0.769961027307693

00:45:38.920 --> 00:45:42.280 the overall response in the total
NOTE Confidence: 0.769961027307693

00:45:42.280 --> 00:45:46.233 population of what what's 40.6% with a
NOTE Confidence: 0.769961027307693

00:45:46.233 --> 00:45:49.659 high quality responses that included a
NOTE Confidence: 0.769961027307693

00:45:49.659 --> 00:45:53.139 stringent CR complete response and VGPR.
NOTE Confidence: 0.769961027307693

00:45:53.140 --> 00:45:55.055 And in those with Extramedullary
NOTE Confidence: 0.769961027307693

00:45:55.055 --> 00:45:57.327 disease overall response rate was still
NOTE Confidence: 0.769961027307693

00:45:57.327 --> 00:45:59.976 notable at 30% and patients who had
NOTE Confidence: 0.769961027307693

00:45:59.976 --> 00:46:02.196 received anti BCH treatment although
NOTE Confidence: 0.769961027307693

00:46:02.196 --> 00:46:04.826 small in in number with 30 patients.
NOTE Confidence: 0.769961027307693

00:46:04.830 --> 00:46:07.238 Portal had an overall response rate of of
NOTE Confidence: 0.769961027307693

00:46:07.240 --> 00:46:11.280 50% and while follow-up is short to date,
NOTE Confidence: 0.769961027307693

00:46:11.280 --> 00:46:13.365 the median progression free survival
NOTE Confidence: 0.769961027307693

00:46:13.365 --> 00:46:15.800 observed was 4.4 months and median
NOTE Confidence: 0.769961027307693

00:46:15.800 --> 00:46:18.600 duration of response was 9.2 months
NOTE Confidence: 0.769961027307693

00:46:18.600 --> 00:46:21.600 when patients achieved VGPR better.
NOTE Confidence: 0.769961027307693

00:46:21.600 --> 00:46:23.875 And Doctor Richardson presented some

NOTE Confidence: 0.769961027307693
00:46:23.875 --> 00:46:26.720 correlative data from this abstract as well,
NOTE Confidence: 0.769961027307693
00:46:26.720 --> 00:46:29.016 showing that Messi is active in patients
NOTE Confidence: 0.769961027307693
00:46:29.016 --> 00:46:31.385 who are either refractory to pomalidomide
NOTE Confidence: 0.769961027307693
00:46:31.385 --> 00:46:34.031 or POMALYST and in those receiving
NOTE Confidence: 0.769961027307693
00:46:34.031 --> 00:46:36.028 pomalidomide as in their last regimen.
NOTE Confidence: 0.769961027307693
00:46:36.030 --> 00:46:38.868 As their last regimen of treatment.
NOTE Confidence: 0.769961027307693
00:46:38.870 --> 00:46:42.510 At a median follow-up of 7.5 months,
NOTE Confidence: 0.769961027307693
00:46:42.510 --> 00:46:44.790 90.1% of patients had discontinued treatment,
NOTE Confidence: 0.769961027307693
00:46:44.790 --> 00:46:46.378 although the majority due
NOTE Confidence: 0.769961027307693
00:46:46.378 --> 00:46:47.569 to progressive myeloma.
NOTE Confidence: 0.769961027307693
00:46:47.570 --> 00:46:49.530 5 patients were reported
NOTE Confidence: 0.769961027307693
00:46:49.530 --> 00:46:51.490 to have adverse events.
NOTE Confidence: 0.769961027307693
00:46:51.490 --> 00:46:52.154 Related events,
NOTE Confidence: 0.769961027307693
00:46:52.154 --> 00:46:52.818 excuse me.
NOTE Confidence: 0.769961027307693
00:46:52.818 --> 00:46:54.810 5 patients were reported to have
NOTE Confidence: 0.769961027307693

00:46:54.874 --> 00:46:56.510 adverse event related deaths,
NOTE Confidence: 0.769961027307693

00:46:56.510 --> 00:46:58.870 including two with PJP pneumonia,
NOTE Confidence: 0.769961027307693

00:46:58.870 --> 00:47:00.320 an additional with pneumonia and
NOTE Confidence: 0.769961027307693

00:47:00.320 --> 00:47:02.104 one due to COVID-19 infection
NOTE Confidence: 0.769961027307693

00:47:02.104 --> 00:47:04.846 and one due to septic shock.
NOTE Confidence: 0.769961027307693

00:47:04.850 --> 00:47:07.298 And while a majority of patients did require
NOTE Confidence: 0.769961027307693

00:47:07.298 --> 00:47:09.029 dose interruptions due to adverse events.
NOTE Confidence: 0.769961027307693

00:47:09.030 --> 00:47:11.022 Those reductions were less
NOTE Confidence: 0.769961027307693

00:47:11.022 --> 00:47:13.512 common and a few patient,
NOTE Confidence: 0.769961027307693

00:47:13.520 --> 00:47:14.736 a few patients discontinued
NOTE Confidence: 0.769961027307693

00:47:14.736 --> 00:47:16.840 drug due to adverse events as is
NOTE Confidence: 0.769961027307693

00:47:16.840 --> 00:47:18.408 outlined here and as you can see
NOTE Confidence: 0.769961027307693

00:47:18.408 --> 00:47:20.297 in the tables here on the bottom,
NOTE Confidence: 0.769961027307693

00:47:20.300 --> 00:47:22.088 treatment emergent adverse events
NOTE Confidence: 0.769961027307693

00:47:22.088 --> 00:47:23.876 were primarily hematologic in
NOTE Confidence: 0.769961027307693

00:47:23.876 --> 00:47:26.011 nature with neutropenia being the

NOTE Confidence: 0.769961027307693
00:47:26.011 --> 00:47:27.964 most common although this was felt
NOTE Confidence: 0.769961027307693
00:47:27.964 --> 00:47:29.710 to be manageable again with those
NOTE Confidence: 0.769961027307693
00:47:29.770 --> 00:47:31.750 adjustments and growth factor support.
NOTE Confidence: 0.769961027307693
00:47:31.750 --> 00:47:33.770 Additionally infections were the
NOTE Confidence: 0.769961027307693
00:47:33.770 --> 00:47:36.295 most common non hematologic adverse
NOTE Confidence: 0.769961027307693
00:47:36.295 --> 00:47:38.547 event with infections of any grade
NOTE Confidence: 0.769961027307693
00:47:38.547 --> 00:47:40.910 seen in about 2/3 of patients.
NOTE Confidence: 0.769961027307693
00:47:40.910 --> 00:47:43.244 Other observed side effects are are
NOTE Confidence: 0.769961027307693
00:47:43.244 --> 00:47:45.888 listed here in the in the tables,
NOTE Confidence: 0.769961027307693
00:47:45.890 --> 00:47:47.815 although they were less common
NOTE Confidence: 0.769961027307693
00:47:47.815 --> 00:47:48.970 and less severe.
NOTE Confidence: 0.769961027307693
00:47:48.970 --> 00:47:50.074 So to summarize,
NOTE Confidence: 0.769961027307693
00:47:50.074 --> 00:47:52.282 Mazda Magnemite or Messi is an
NOTE Confidence: 0.769961027307693
00:47:52.282 --> 00:47:55.102 oral potent novel cell mod which in
NOTE Confidence: 0.769961027307693
00:47:55.102 --> 00:47:57.356 preclinical studies has a distinct
NOTE Confidence: 0.769961027307693

00:47:57.356 --> 00:48:00.306 profile from our immunomodulatory agents.

NOTE Confidence: 0.769961027307693

00:48:00.310 --> 00:48:02.530 And when combined with dexamethasone

NOTE Confidence: 0.769961027307693

00:48:02.530 --> 00:48:04.750 overall response rate was notable

NOTE Confidence: 0.85525948

00:48:04.823 --> 00:48:08.294 at 40.6% in the total cohort and 30% in

NOTE Confidence: 0.85525948

00:48:08.294 --> 00:48:10.230 patients with extramedullary disease,

NOTE Confidence: 0.85525948

00:48:10.230 --> 00:48:11.310 the safety profile.

NOTE Confidence: 0.85525948

00:48:11.310 --> 00:48:13.470 Is manageable with most higher grade

NOTE Confidence: 0.85525948

00:48:13.470 --> 00:48:15.466 adverse events being hematologic in

NOTE Confidence: 0.85525948

00:48:15.466 --> 00:48:17.436 nature and most commonly neutropenia

NOTE Confidence: 0.85525948

00:48:17.436 --> 00:48:19.548 which did require some dose adjustments

NOTE Confidence: 0.85525948

00:48:19.548 --> 00:48:21.539 and GCF support when when needed.

NOTE Confidence: 0.85525948

00:48:21.539 --> 00:48:22.526 Given these findings,

NOTE Confidence: 0.85525948

00:48:22.526 --> 00:48:24.500 Mezi is now being evaluated in

NOTE Confidence: 0.85525948

00:48:24.560 --> 00:48:26.204 combination with standard myeloma

NOTE Confidence: 0.85525948

00:48:26.204 --> 00:48:28.259 therapies including in phase three

NOTE Confidence: 0.85525948

00:48:28.259 --> 00:48:29.962 trials with Bortezomib and carfilzomib

NOTE Confidence: 0.85525948

00:48:29.962 --> 00:48:32.336 and this appears to be a promising

NOTE Confidence: 0.85525948

00:48:32.336 --> 00:48:34.966 agent in patients with heavily

NOTE Confidence: 0.85525948

00:48:34.966 --> 00:48:37.070 pretreated relapsed refractory myeloma

NOTE Confidence: 0.85525948

00:48:37.142 --> 00:48:39.500 including those who may be refractory

NOTE Confidence: 0.85525948

00:48:39.500 --> 00:48:41.740 to to imids including POMALYST.

NOTE Confidence: 0.85525948

00:48:41.740 --> 00:48:43.780 So I'll I will shift gears a bit

NOTE Confidence: 0.85525948

00:48:43.780 --> 00:48:46.019 now with this last abstract and

NOTE Confidence: 0.85525948

00:48:46.019 --> 00:48:48.094 discuss like Chainer ALE amyloidosis,

NOTE Confidence: 0.85525948

00:48:48.100 --> 00:48:50.137 which as you guys likely know is

NOTE Confidence: 0.85525948

00:48:50.137 --> 00:48:51.768 a rare progressive disorder where

NOTE Confidence: 0.85525948

00:48:51.768 --> 00:48:53.856 clonal plasma cells in the bone

NOTE Confidence: 0.85525948

00:48:53.856 --> 00:48:55.324 marrow produce immunoglobulin light

NOTE Confidence: 0.85525948

00:48:55.324 --> 00:48:57.448 chains that misfold and and and

NOTE Confidence: 0.85525948

00:48:57.448 --> 00:48:59.387 then form amyloid fibrils that

NOTE Confidence: 0.85525948

00:48:59.387 --> 00:49:01.432 become insoluble and deposit in

NOTE Confidence: 0.85525948

00:49:01.432 --> 00:49:03.190 extracellular tissues and organs
NOTE Confidence: 0.85525948

00:49:03.190 --> 00:49:04.958 resulting in significant dysfunction.
NOTE Confidence: 0.85525948

00:49:04.960 --> 00:49:07.208 And we have made advances in the treatment
NOTE Confidence: 0.85525948

00:49:07.208 --> 00:49:09.415 of AL amyloid with exciting data from
NOTE Confidence: 0.85525948

00:49:09.415 --> 00:49:11.999 last year's ASH on the Andromeda trial.
NOTE Confidence: 0.85525948

00:49:12.000 --> 00:49:13.940 Uh which showed improved team
NOTE Confidence: 0.85525948

00:49:13.940 --> 00:49:16.292 hematologic and organ responses with the
NOTE Confidence: 0.85525948

00:49:16.292 --> 00:49:18.404 addition of daratumumab to cyber deem.
NOTE Confidence: 0.85525948

00:49:18.410 --> 00:49:18.796 However,
NOTE Confidence: 0.85525948

00:49:18.796 --> 00:49:20.726 these available therapies target the
NOTE Confidence: 0.85525948

00:49:20.726 --> 00:49:23.255 clonal plasma cells in order to stop
NOTE Confidence: 0.85525948

00:49:23.255 --> 00:49:25.109 or halt production of light chains,
NOTE Confidence: 0.85525948

00:49:25.110 --> 00:49:27.090 new light chains but they don't
NOTE Confidence: 0.85525948

00:49:27.090 --> 00:49:28.777 address the amyloid that's already
NOTE Confidence: 0.85525948

00:49:28.777 --> 00:49:30.589 been deposited and in and organs
NOTE Confidence: 0.85525948

00:49:30.589 --> 00:49:32.809 that lead to significant morbidity.

NOTE Confidence: 0.85525948

00:49:32.810 --> 00:49:34.295 And in patients with advanced

NOTE Confidence: 0.85525948

00:49:34.295 --> 00:49:34.889 cardiac disease,

NOTE Confidence: 0.85525948

00:49:34.890 --> 00:49:37.056 high mortality with a median overall

NOTE Confidence: 0.85525948

00:49:37.056 --> 00:49:38.864 survival in patients with Mayo

NOTE Confidence: 0.85525948

00:49:38.864 --> 00:49:40.718 stage four disease of only 5.8

NOTE Confidence: 0.85525948

00:49:40.718 --> 00:49:42.110 months and the abstract.

NOTE Confidence: 0.85525948

00:49:42.110 --> 00:49:43.750 We'll discuss was presented by

NOTE Confidence: 0.85525948

00:49:43.750 --> 00:49:45.807 Doctor Morie Gertz from the Mayo

NOTE Confidence: 0.85525948

00:49:45.807 --> 00:49:47.597 Clinic on Beartown bertam amount,

NOTE Confidence: 0.85525948

00:49:47.600 --> 00:49:50.035 which is a humanized monoclonal

NOTE Confidence: 0.85525948

00:49:50.035 --> 00:49:51.496 antibody administered intravenously

NOTE Confidence: 0.85525948

00:49:51.496 --> 00:49:54.029 every 28 days and binds conserved

NOTE Confidence: 0.85525948

00:49:54.029 --> 00:49:56.261 epitopes on both Kappa and Lambda

NOTE Confidence: 0.85525948

00:49:56.327 --> 00:49:58.732 immunoglobulin light chains and that

NOTE Confidence: 0.85525948

00:49:58.732 --> 00:50:01.137 leads to neutralization of circulating

NOTE Confidence: 0.85525948

00:50:01.140 --> 00:50:03.732 light chain aggregates as well as
NOTE Confidence: 0.85525948

00:50:03.732 --> 00:50:05.961 depletes the insoluble amyloid deposited
NOTE Confidence: 0.85525948

00:50:05.961 --> 00:50:08.985 in the organ organs thought to be
NOTE Confidence: 0.85525948

00:50:08.985 --> 00:50:10.929 through phagocytosis by macrophages.
NOTE Confidence: 0.85525948

00:50:10.930 --> 00:50:13.065 And the study schema here on the
NOTE Confidence: 0.85525948

00:50:13.065 --> 00:50:15.018 top outlines the phase three vital
NOTE Confidence: 0.85525948

00:50:15.018 --> 00:50:16.968 study which is a multi center
NOTE Confidence: 0.85525948

00:50:16.970 --> 00:50:17.776 double-blind placebo-controlled
NOTE Confidence: 0.85525948

00:50:17.776 --> 00:50:19.791 trial in patients with newly
NOTE Confidence: 0.85525948

00:50:19.791 --> 00:50:21.570 diagnosed treatment naive AL amyloid.
NOTE Confidence: 0.85525948

00:50:21.570 --> 00:50:23.790 All patients enrolled had cardiac involvement
NOTE Confidence: 0.85525948

00:50:23.790 --> 00:50:25.929 and were stratified by Mayo stage,
NOTE Confidence: 0.85525948

00:50:25.930 --> 00:50:28.800 renal stage and six minute walk test.
NOTE Confidence: 0.85525948

00:50:28.800 --> 00:50:30.810 260 patients total were enrolled
NOTE Confidence: 0.85525948

00:50:30.810 --> 00:50:32.820 and randomized to receive birtamod
NOTE Confidence: 0.85525948

00:50:32.820 --> 00:50:35.193 amab in addition to standard of care

NOTE Confidence: 0.85525948

00:50:35.193 --> 00:50:37.390 or placebo with standard of care.

NOTE Confidence: 0.85525948

00:50:37.390 --> 00:50:39.530 There was an interim futility

NOTE Confidence: 0.85525948

00:50:39.530 --> 00:50:41.191 analysis back in 2018.

NOTE Confidence: 0.85525948

00:50:41.191 --> 00:50:43.046 That actually resulted in early

NOTE Confidence: 0.85525948

00:50:43.046 --> 00:50:44.911 study termination given concern that

NOTE Confidence: 0.85525948

00:50:44.911 --> 00:50:46.819 the primary endpoint which was all

NOTE Confidence: 0.85525948

00:50:46.819 --> 00:50:48.839 all cause mortality or time to all

NOTE Confidence: 0.85525948

00:50:48.839 --> 00:50:50.626 cause mortality would not be met in

NOTE Confidence: 0.85525948

00:50:50.626 --> 00:50:52.488 a in a reasonable amount of time.

NOTE Confidence: 0.85525948

00:50:52.490 --> 00:50:55.829 And so afterwards a post hoc analysis

NOTE Confidence: 0.85525948

00:50:55.829 --> 00:50:58.373 was performed on 77 patients that

NOTE Confidence: 0.85525948

00:50:58.373 --> 00:51:00.599 had Mayo Stage 4 cardiac amyloid.

NOTE Confidence: 0.85525948

00:51:00.600 --> 00:51:02.430 And this has previously been reported

NOTE Confidence: 0.85525948

00:51:02.430 --> 00:51:04.859 to show as you can see in the

NOTE Confidence: 0.85525948

00:51:04.859 --> 00:51:06.581 Kaplan Meier curve here a survival

NOTE Confidence: 0.85525948

00:51:06.645 --> 00:51:08.169 benefit with significant reduction
NOTE Confidence: 0.85525948

00:51:08.169 --> 00:51:10.455 in time to all cause mortality
NOTE Confidence: 0.859358008

00:51:10.460 --> 00:51:13.900 in this cohort. With 74% of patients
NOTE Confidence: 0.859358008

00:51:13.900 --> 00:51:15.970 in the Bertambah group being alive
NOTE Confidence: 0.859358008

00:51:15.970 --> 00:51:18.344 at month nine with only compared to
NOTE Confidence: 0.859358008

00:51:18.344 --> 00:51:21.197 only 49% in the placebo arm with the
NOTE Confidence: 0.859358008

00:51:21.197 --> 00:51:23.839 hazard ratio that you see listed here.
NOTE Confidence: 0.859358008

00:51:23.840 --> 00:51:25.820 So in this year's abstract Dr.
NOTE Confidence: 0.859358008

00:51:25.820 --> 00:51:27.480 Gerson is coauthors showed using
NOTE Confidence: 0.859358008

00:51:27.480 --> 00:51:29.906 the data from the post hoc analysis
NOTE Confidence: 0.859358008

00:51:29.906 --> 00:51:32.006 that reduction in time to all
NOTE Confidence: 0.859358008

00:51:32.006 --> 00:51:33.679 cause mortality at nine months.
NOTE Confidence: 0.859358008

00:51:33.680 --> 00:51:35.660 I'm favoring the pertama amab arm
NOTE Confidence: 0.859358008

00:51:35.660 --> 00:51:37.720 persisted in these Mayo stage four
NOTE Confidence: 0.859358008

00:51:37.720 --> 00:51:39.425 patients ever even after adjusting
NOTE Confidence: 0.859358008

00:51:39.425 --> 00:51:41.505 for a variety of demographic

NOTE Confidence: 0.859358008

00:51:41.505 --> 00:51:42.996 and disease characteristics.

NOTE Confidence: 0.859358008

00:51:43.000 --> 00:51:45.784 As you can see in the forest plots

NOTE Confidence: 0.859358008

00:51:45.784 --> 00:51:49.102 here that come from small numbers but

NOTE Confidence: 0.859358008

00:51:49.102 --> 00:51:51.637 have again impressive hazard ratios.

NOTE Confidence: 0.859358008

00:51:51.640 --> 00:51:54.864 There was also in the post tech analysis.

NOTE Confidence: 0.859358008

00:51:54.870 --> 00:51:56.820 Patients who received Birtamod had

NOTE Confidence: 0.859358008

00:51:56.820 --> 00:51:58.770 less deterioration in quality of

NOTE Confidence: 0.859358008

00:51:58.833 --> 00:52:00.989 life and improved 6 minute walk test.

NOTE Confidence: 0.859358008

00:52:00.990 --> 00:52:03.132 And so with the available data for

NOTE Confidence: 0.859358008

00:52:03.132 --> 00:52:05.583 Tim Amab has been safe and well

NOTE Confidence: 0.859358008

00:52:05.583 --> 00:52:07.408 tolerated even in these patients

NOTE Confidence: 0.859358008

00:52:07.408 --> 00:52:09.989 with advanced cardiac disease and

NOTE Confidence: 0.859358008

00:52:09.989 --> 00:52:14.621 it has this data has served as the

NOTE Confidence: 0.859358008

00:52:14.621 --> 00:52:17.775 foundation for the Affirm ALS trial

NOTE Confidence: 0.859358008

00:52:17.775 --> 00:52:20.050 and we have this trial open here

NOTE Confidence: 0.859358008

00:52:20.050 --> 00:52:22.651 at Yale as well as in a number of
NOTE Confidence: 0.859358008

00:52:22.651 --> 00:52:24.948 our our care centers in Trumbull.
NOTE Confidence: 0.859358008

00:52:24.950 --> 00:52:27.582 Saint Francis Francis and a female is
NOTE Confidence: 0.859358008

00:52:27.582 --> 00:52:30.142 looking to enroll patients with newly
NOTE Confidence: 0.859358008

00:52:30.142 --> 00:52:32.402 diagnosed treatment naive al amyloid
NOTE Confidence: 0.859358008

00:52:32.402 --> 00:52:34.935 with with Mayo stage four disease
NOTE Confidence: 0.859358008

00:52:34.935 --> 00:52:37.275 with the criteria listed here and
NOTE Confidence: 0.859358008

00:52:37.280 --> 00:52:38.904 and looking again to see if we see
NOTE Confidence: 0.859358008

00:52:38.904 --> 00:52:40.549 this this survival benefit that was
NOTE Confidence: 0.859358008

00:52:40.549 --> 00:52:42.325 demonstrated in the post hoc analysis.
NOTE Confidence: 0.859358008

00:52:42.330 --> 00:52:43.745 And patients will be randomized
NOTE Confidence: 0.859358008

00:52:43.745 --> 00:52:45.929 2 to one to receive vertamae in
NOTE Confidence: 0.859358008

00:52:45.929 --> 00:52:47.337 addition to standard care.
NOTE Confidence: 0.859358008

00:52:47.340 --> 00:52:49.876 And I do think this is an incredibly
NOTE Confidence: 0.859358008

00:52:49.876 --> 00:52:51.847 important trial for a very complex
NOTE Confidence: 0.859358008

00:52:51.847 --> 00:52:54.108 very hard to treat population and I

NOTE Confidence: 0.859358008

00:52:54.108 --> 00:52:56.138 would be happy to talk with anybody.

NOTE Confidence: 0.859358008

00:52:56.140 --> 00:52:58.642 Interested who might have eligible patients

NOTE Confidence: 0.859358008

00:52:58.642 --> 00:53:01.248 or have questions about the the trial?

NOTE Confidence: 0.859358008

00:53:01.250 --> 00:53:01.551 So,

NOTE Confidence: 0.859358008

00:53:01.551 --> 00:53:02.454 so in summary,

NOTE Confidence: 0.859358008

00:53:02.454 --> 00:53:04.725 we saw many exciting abstracts at ASH

NOTE Confidence: 0.859358008

00:53:04.725 --> 00:53:07.155 looking at new myeloma target antigens

NOTE Confidence: 0.859358008

00:53:07.155 --> 00:53:08.998 from biospecific antibodies and car

NOTE Confidence: 0.859358008

00:53:08.998 --> 00:53:10.979 T as well as abstract looking at

NOTE Confidence: 0.859358008

00:53:10.979 --> 00:53:12.806 improved manufacturing and management

NOTE Confidence: 0.859358008

00:53:12.806 --> 00:53:15.366 of side effects including CRS.

NOTE Confidence: 0.859358008

00:53:15.370 --> 00:53:17.660 I I will end so that we can move to

NOTE Confidence: 0.859358008

00:53:17.735 --> 00:53:20.021 the questions and answers by just

NOTE Confidence: 0.859358008

00:53:20.021 --> 00:53:22.530 saying that although not covered today,

NOTE Confidence: 0.859358008

00:53:22.530 --> 00:53:24.700 there were up to 30 abstracts on

NOTE Confidence: 0.859358008

00:53:24.700 --> 00:53:26.549 looking at health disparities in
NOTE Confidence: 0.859358008

00:53:26.549 --> 00:53:28.689 multiple myeloma which remains really
NOTE Confidence: 0.859358008

00:53:28.689 --> 00:53:31.089 a critical unmet need and ongoing.
NOTE Confidence: 0.859358008

00:53:31.090 --> 00:53:32.710 Investigation is really imperative.
NOTE Confidence: 0.859358008

00:53:32.710 --> 00:53:35.490 The QR code I've included here links
NOTE Confidence: 0.859358008

00:53:35.490 --> 00:53:37.464 to a video by Doctor Joel McHale
NOTE Confidence: 0.859358008

00:53:37.464 --> 00:53:39.140 and the International Myeloma
NOTE Confidence: 0.859358008

00:53:39.140 --> 00:53:41.750 Foundation addressing some of these
NOTE Confidence: 0.859358008

00:53:41.750 --> 00:53:43.316 really important abstracts.
NOTE Confidence: 0.859358008

00:53:43.320 --> 00:53:45.336 So thank you again all for your time and
NOTE Confidence: 0.859358008

00:53:45.336 --> 00:53:47.797 I look forward to answering some questions.
NOTE Confidence: 0.811555536666667

00:53:57.110 --> 00:53:59.440 Thank you Sabrina and Nofar
NOTE Confidence: 0.811555536666667

00:53:59.440 --> 00:54:01.304 for those excellent reviews.
NOTE Confidence: 0.811555536666667

00:54:01.310 --> 00:54:02.870 We do have time for questions,
NOTE Confidence: 0.811555536666667

00:54:02.870 --> 00:54:04.490 so I would encourage everyone
NOTE Confidence: 0.811555536666667

00:54:04.490 --> 00:54:06.110 to please place your questions,

NOTE Confidence: 0.811555536666667
00:54:06.110 --> 00:54:08.486 if you have any in the Q&A portion
NOTE Confidence: 0.811555536666667
00:54:08.486 --> 00:54:11.158 that can be found below in the screen.
NOTE Confidence: 0.811555536666667
00:54:11.160 --> 00:54:12.540 As we wait for questions,
NOTE Confidence: 0.811555536666667
00:54:12.540 --> 00:54:14.997 I will start by asking a few.
NOTE Confidence: 0.811555536666667
00:54:15.000 --> 00:54:18.416 Maybe we'll start with Elon and Natalia.
NOTE Confidence: 0.811555536666667
00:54:18.420 --> 00:54:20.362 We heard a lot about side effects
NOTE Confidence: 0.811555536666667
00:54:20.362 --> 00:54:22.648 from the bispecific T cell engagers,
NOTE Confidence: 0.811555536666667
00:54:22.650 --> 00:54:25.240 the cartes and even the cell mods
NOTE Confidence: 0.811555536666667
00:54:25.240 --> 00:54:27.210 in relationship to infections.
NOTE Confidence: 0.811555536666667
00:54:27.210 --> 00:54:29.590 So how would you propose we manage
NOTE Confidence: 0.811555536666667
00:54:29.590 --> 00:54:32.422 that risk to help keep our patients
NOTE Confidence: 0.811555536666667
00:54:32.422 --> 00:54:35.026 safe as these therapies move forward?
NOTE Confidence: 0.890344838571429
00:54:42.240 --> 00:54:43.339 I mean I guess I can start.
NOTE Confidence: 0.890344838571429
00:54:43.340 --> 00:54:45.640 We know that there's a risk of a
NOTE Confidence: 0.890344838571429
00:54:45.640 --> 00:54:47.099 hypogammaglobulinemia with this patient.
NOTE Confidence: 0.890344838571429

00:54:47.099 --> 00:54:48.857 So I think that keeping a
NOTE Confidence: 0.890344838571429

00:54:48.857 --> 00:54:50.060 close signing IG level,
NOTE Confidence: 0.890344838571429

00:54:50.060 --> 00:54:52.184 making sure that it's you know
NOTE Confidence: 0.890344838571429

00:54:52.184 --> 00:54:54.424 consistently at least 400 or
NOTE Confidence: 0.890344838571429

00:54:54.424 --> 00:54:57.704 even 500 compliance with you know
NOTE Confidence: 0.890344838571429

00:54:57.704 --> 00:55:00.600 antiviral anti microbial prophylaxis
NOTE Confidence: 0.890344838571429

00:55:00.600 --> 00:55:04.800 and I think also just educating
NOTE Confidence: 0.890344838571429

00:55:04.800 --> 00:55:06.420 you know the various colleagues.
NOTE Confidence: 0.890344838571429

00:55:06.420 --> 00:55:08.970 And members of the community
NOTE Confidence: 0.890344838571429

00:55:08.970 --> 00:55:10.859 and the oncology team about the,
NOTE Confidence: 0.890344838571429

00:55:10.860 --> 00:55:13.062 you know, the risk for infection
NOTE Confidence: 0.890344838571429

00:55:13.062 --> 00:55:15.020 complications in these novel agents.
NOTE Confidence: 0.7885724475

00:55:20.830 --> 00:55:22.374 I think they tell you you're a mute.
NOTE Confidence: 0.689506

00:55:31.830 --> 00:55:33.060 Help, you're still muted.
NOTE Confidence: 0.68477774

00:55:47.060 --> 00:55:50.786 And. Natalia, you were still on mute.
NOTE Confidence: 0.68477774

00:55:50.790 --> 00:55:52.240 So unfortunately we're not been

NOTE Confidence: 0.68477774

00:55:52.240 --> 00:55:54.300 able to hear what you have said.

NOTE Confidence: 0.9241706675

00:55:56.170 --> 00:55:57.418 And we can move

NOTE Confidence: 0.899809279

00:55:57.430 --> 00:56:00.926 on. We did have one question from the

NOTE Confidence: 0.899809279

00:56:00.926 --> 00:56:03.902 audience which is asking if calcium

NOTE Confidence: 0.899809279

00:56:03.902 --> 00:56:06.926 deficiency is seen in multiple myeloma.

NOTE Confidence: 0.3717668

00:56:09.420 --> 00:56:12.842 Umm. I don't know if anyone wants

NOTE Confidence: 0.3717668

00:56:12.842 --> 00:56:14.630 to take the question regarding

NOTE Confidence: 0.3717668

00:56:14.630 --> 00:56:16.590 calcium and multiple myeloma.

NOTE Confidence: 0.863859932

00:56:20.110 --> 00:56:24.440 I mean I think that usually with

NOTE Confidence: 0.7988402

00:56:24.550 --> 00:56:25.570 myeloma we see

NOTE Confidence: 0.86062957

00:56:25.580 --> 00:56:27.841 hypercalcemia and I think if it's poorly

NOTE Confidence: 0.86062957

00:56:27.841 --> 00:56:30.800 controlled we can see hypercalcemia. You

NOTE Confidence: 0.836550186666667

00:56:30.810 --> 00:56:32.878 know the bisphosphonates and the bone

NOTE Confidence: 0.836550186666667

00:56:32.878 --> 00:56:34.838 modifying agents can cause hypocalcemia,

NOTE Confidence: 0.910736112857143

00:56:34.850 --> 00:56:38.546 but but typically we would see hypercalcemia.

NOTE Confidence: 0.783615386666667

00:56:40.140 --> 00:56:42.648 Thank you, Elon.
NOTE Confidence: 0.783615386666667

00:56:42.650 --> 00:56:44.340 So I may ask a question that's a
NOTE Confidence: 0.783615386666667

00:56:44.340 --> 00:56:45.786 little bit unfair to the group.
NOTE Confidence: 0.783615386666667

00:56:45.786 --> 00:56:47.698 And we can have each of the panelists
NOTE Confidence: 0.783615386666667

00:56:47.698 --> 00:56:49.784 answer with all of these new targets
NOTE Confidence: 0.783615386666667

00:56:49.784 --> 00:56:51.958 and they relapsed refractory setting.
NOTE Confidence: 0.783615386666667

00:56:51.960 --> 00:56:53.902 How do you propose that we sequence
NOTE Confidence: 0.783615386666667

00:56:53.902 --> 00:56:56.849 them and most of these studies have
NOTE Confidence: 0.783615386666667

00:56:56.849 --> 00:56:59.697 been done after potentially BCM a.
NOTE Confidence: 0.783615386666667

00:56:59.700 --> 00:57:01.362 But again, I would be interested
NOTE Confidence: 0.783615386666667

00:57:01.362 --> 00:57:02.470 in everyone's thoughts as
NOTE Confidence: 0.783615386666667

00:57:02.520 --> 00:57:03.620 far as they're optimal.
NOTE Confidence: 0.783615386666667

00:57:03.620 --> 00:57:05.900 And maybe we can start with Elon and
NOTE Confidence: 0.783615386666667

00:57:05.900 --> 00:57:08.160 Natalia and then go to no farms, Sabrina.
NOTE Confidence: 0.566959742857143

00:57:14.620 --> 00:57:16.145 Another Natalia sorted out her
NOTE Confidence: 0.566959742857143

00:57:16.145 --> 00:57:21.218 mute option, but. I guess not.

NOTE Confidence: 0.566959742857143

00:57:21.220 --> 00:57:23.500 So I think obviously that's an

NOTE Confidence: 0.566959742857143

00:57:23.500 --> 00:57:25.761 ongoing area of of evaluation and

NOTE Confidence: 0.566959742857143

00:57:25.761 --> 00:57:27.216 research with these novel agents.

NOTE Confidence: 0.566959742857143

00:57:27.220 --> 00:57:29.116 We are looking at them in

NOTE Confidence: 0.566959742857143

00:57:29.116 --> 00:57:30.380 earlier lines of therapy,

NOTE Confidence: 0.566959742857143

00:57:30.380 --> 00:57:31.820 you know in clinical trials,

NOTE Confidence: 0.566959742857143

00:57:31.820 --> 00:57:34.040 cartoon etcetera.

NOTE Confidence: 0.566959742857143

00:57:34.040 --> 00:57:35.305 I think that it depends

NOTE Confidence: 0.566959742857143

00:57:35.305 --> 00:57:36.480 on a couple of factors.

NOTE Confidence: 0.566959742857143

00:57:36.480 --> 00:57:37.920 You know how did the patients

NOTE Confidence: 0.566959742857143

00:57:37.920 --> 00:57:38.880 respond to prior treatments,

NOTE Confidence: 0.566959742857143

00:57:38.880 --> 00:57:42.276 what prior treatments have they had.

NOTE Confidence: 0.566959742857143

00:57:42.280 --> 00:57:43.480 You know, high risk,

NOTE Confidence: 0.566959742857143

00:57:43.480 --> 00:57:44.310 standard risk,

NOTE Confidence: 0.80878907

00:57:45.400 --> 00:57:46.560 I think that the

NOTE Confidence: 0.731248512

00:57:46.570 --> 00:57:48.355 data is pretty encouraging and
NOTE Confidence: 0.731248512

00:57:48.355 --> 00:57:50.140 promising for biospecifics and cartes.
NOTE Confidence: 0.731248512

00:57:50.140 --> 00:57:52.820 So I think that. You know,
NOTE Confidence: 0.731248512

00:57:52.820 --> 00:57:53.820 if they're candidates for that,
NOTE Confidence: 0.731248512

00:57:53.820 --> 00:57:56.760 we should try to push for that.
NOTE Confidence: 0.731248512

00:57:56.760 --> 00:57:59.810 But a lot, a lot will be. Coming
NOTE Confidence: 0.798742452

00:57:59.820 --> 00:58:00.480 and we'll have a lot
NOTE Confidence: 0.917500438

00:58:00.490 --> 00:58:01.970 more information in the upcoming,
NOTE Confidence: 0.917500438

00:58:01.970 --> 00:58:03.820 you know, months and annual meetings.
NOTE Confidence: 0.701242738333333

00:58:05.560 --> 00:58:07.400 Thank you, Ellen, and no far Sabrina.
NOTE Confidence: 0.83174792125

00:58:09.440 --> 00:58:11.699 Yeah. So I think at the end of the
NOTE Confidence: 0.83174792125

00:58:11.699 --> 00:58:14.152 day the answer is we don't know as
NOTE Confidence: 0.83174792125

00:58:14.152 --> 00:58:16.264 you know they're they're all quite
NOTE Confidence: 0.83174792125

00:58:16.264 --> 00:58:18.986 effective and we don't really know which
NOTE Confidence: 0.83174792125

00:58:18.986 --> 00:58:21.374 subtypes of patients would do better.
NOTE Confidence: 0.83174792125

00:58:21.380 --> 00:58:23.907 But we do have some information that

NOTE Confidence: 0.83174792125

00:58:23.907 --> 00:58:25.999 patients who have gained 1Q have

NOTE Confidence: 0.83174792125

00:58:25.999 --> 00:58:28.197 high expressions of the FC RH 5.

NOTE Confidence: 0.83174792125

00:58:28.200 --> 00:58:31.420 So perhaps you know being a little

NOTE Confidence: 0.83174792125

00:58:31.420 --> 00:58:34.120 bit more specific in terms of patient

NOTE Confidence: 0.83174792125

00:58:34.120 --> 00:58:36.663 selection to some of these again more

NOTE Confidence: 0.83174792125

00:58:36.663 --> 00:58:39.455 studies really need to be done in subgroup.

NOTE Confidence: 0.83174792125

00:58:39.460 --> 00:58:39.961 Populations.

NOTE Confidence: 0.83174792125

00:58:39.961 --> 00:58:43.468 I think it is encouraging that the

NOTE Confidence: 0.83174792125

00:58:43.468 --> 00:58:46.813 infection risk is lower with tell

NOTE Confidence: 0.83174792125

00:58:46.813 --> 00:58:49.073 kalamas supposed to Tequesta amab.

NOTE Confidence: 0.83174792125

00:58:49.080 --> 00:58:51.628 So for patients where you're more worried

NOTE Confidence: 0.83174792125

00:58:51.628 --> 00:58:54.211 about that maybe in a post transplant

NOTE Confidence: 0.83174792125

00:58:54.211 --> 00:58:56.353 setting where you know there's other

NOTE Confidence: 0.83174792125

00:58:56.360 --> 00:58:57.794 additives infection complications.

NOTE Confidence: 0.83174792125

00:58:57.794 --> 00:59:02.089 So I think more to come we don't know.

NOTE Confidence: 0.79330085

00:59:04.910 --> 00:59:06.470 You know, I would completely,
NOTE Confidence: 0.79330085

00:59:06.470 --> 00:59:07.040 completely agree.
NOTE Confidence: 0.79330085

00:59:07.040 --> 00:59:09.035 You know, I think there's a question
NOTE Confidence: 0.79330085

00:59:09.035 --> 00:59:10.400 of not only how to sequence
NOTE Confidence: 0.79330085

00:59:10.400 --> 00:59:11.980 our car T and by specifics,
NOTE Confidence: 0.79330085

00:59:11.980 --> 00:59:13.695 but now sequence in terms of targets.
NOTE Confidence: 0.79330085

00:59:13.700 --> 00:59:15.542 So, you know, I agree with
NOTE Confidence: 0.79330085

00:59:15.542 --> 00:59:17.250 Doctor Barr that I think.
NOTE Confidence: 0.79330085

00:59:17.250 --> 00:59:18.996 You know thinking about choosing a
NOTE Confidence: 0.79330085

00:59:18.996 --> 00:59:21.053 carte or by specific I think depends
NOTE Confidence: 0.79330085

00:59:21.053 --> 00:59:23.013 a little bit on the patient's disease
NOTE Confidence: 0.79330085

00:59:23.069 --> 00:59:25.211 at that time and the time that it may
NOTE Confidence: 0.79330085

00:59:25.211 --> 00:59:28.208 require for them to get the the treatment.
NOTE Confidence: 0.79330085

00:59:28.210 --> 00:59:29.842 I think you know it's exciting
NOTE Confidence: 0.79330085

00:59:29.842 --> 00:59:31.580 now to have different targets that
NOTE Confidence: 0.79330085

00:59:31.580 --> 00:59:33.350 do have a unique safety profile.

NOTE Confidence: 0.79330085

00:59:33.350 --> 00:59:35.150 You know and I think a lot of these

NOTE Confidence: 0.79330085

00:59:35.150 --> 00:59:36.814 newer targets are showing response in

NOTE Confidence: 0.79330085

00:59:36.814 --> 00:59:39.010 patients who had prior BCM a cell therapy.

NOTE Confidence: 0.79330085

00:59:39.010 --> 00:59:40.864 So you know I think we have the most

NOTE Confidence: 0.79330085

00:59:40.864 --> 00:59:42.726 data obviously from our CMA products,

NOTE Confidence: 0.79330085

00:59:42.730 --> 00:59:44.881 but I think there are going to be patient

NOTE Confidence: 0.79330085

00:59:44.881 --> 00:59:46.233 populations where these new targets I

NOTE Confidence: 0.79330085

00:59:46.233 --> 00:59:48.338 think are going to be important and perhaps.

NOTE Confidence: 0.79330085

00:59:48.340 --> 00:59:48.770 You know,

NOTE Confidence: 0.79330085

00:59:48.770 --> 00:59:50.580 our first choice moving forward.

NOTE Confidence: 0.79330085

00:59:50.580 --> 00:59:51.520 Wonderful.

NOTE Confidence: 0.830471895454545

00:59:51.530 --> 00:59:52.493 Thank you all.

NOTE Confidence: 0.830471895454545

00:59:52.493 --> 00:59:54.419 Will you have another question from

NOTE Confidence: 0.830471895454545

00:59:54.419 --> 00:59:56.248 the audience with the results of

NOTE Confidence: 0.830471895454545

00:59:56.250 --> 00:59:59.029 the I FM 2009 and determination,

NOTE Confidence: 0.830471895454545

00:59:59.029 --> 01:00:02.382 how do you see MRD driving transplant

NOTE Confidence: 0.830471895454545

01:00:02.382 --> 01:00:05.137 and sequencing of therapies in general?

NOTE Confidence: 0.830471895454545

01:00:05.140 --> 01:00:06.508 So I don't know if Natalia

NOTE Confidence: 0.830471895454545

01:00:06.508 --> 01:00:08.050 or Nofar you have a response?

NOTE Confidence: 0.925201375

01:00:09.340 --> 01:00:11.920 Yeah, I can talk about this.

NOTE Confidence: 0.925201375

01:00:11.920 --> 01:00:15.456 So I think MRD is going to be

NOTE Confidence: 0.925201375

01:00:15.456 --> 01:00:18.400 driving how we treat patients.

NOTE Confidence: 0.925201375

01:00:18.400 --> 01:00:20.311 I think what we see is in

NOTE Confidence: 0.925201375

01:00:20.311 --> 01:00:21.760 both of those studies,

NOTE Confidence: 0.925201375

01:00:21.760 --> 01:00:23.745 patients who are MRD negative

NOTE Confidence: 0.925201375

01:00:23.745 --> 01:00:28.360 just do better in the IM 2009.

NOTE Confidence: 0.925201375

01:00:28.360 --> 01:00:31.139 30% of patients who had VRD in

NOTE Confidence: 0.925201375

01:00:31.139 --> 01:00:33.828 transplant and one year only one

NOTE Confidence: 0.925201375

01:00:33.828 --> 01:00:35.708 year maintenance still remain

NOTE Confidence: 0.925201375

01:00:35.708 --> 01:00:38.510 in remission 8 years after. So.

NOTE Confidence: 0.925201375

01:00:38.510 --> 01:00:40.490 So clearly we are over treating

NOTE Confidence: 0.925201375
01:00:40.490 --> 01:00:42.747 some patients and we need to figure
NOTE Confidence: 0.925201375
01:00:42.747 --> 01:00:44.972 out who those patients are and I
NOTE Confidence: 0.925201375
01:00:44.972 --> 01:00:46.911 think even with transplant, right.
NOTE Confidence: 0.925201375
01:00:46.911 --> 01:00:49.857 So if we achieve MRD negativity
NOTE Confidence: 0.925201375
01:00:49.857 --> 01:00:50.839 with quadruplets,
NOTE Confidence: 0.925201375
01:00:50.840 --> 01:00:52.796 I think we need to assess
NOTE Confidence: 0.925201375
01:00:52.796 --> 01:00:53.774 this transplant better.
NOTE Confidence: 0.925201375
01:00:53.780 --> 01:00:55.580 What is the marginal benefit of
NOTE Confidence: 0.925201375
01:00:55.580 --> 01:00:56.480 transferring those patients?
NOTE Confidence: 0.925201375
01:00:56.480 --> 01:00:57.764 These studies are underway.
NOTE Confidence: 0.925201375
01:00:57.764 --> 01:00:59.048 We will find out,
NOTE Confidence: 0.925201375
01:00:59.050 --> 01:01:01.048 but it will take many years.
NOTE Confidence: 0.925201375
01:01:01.050 --> 01:01:03.731 Right now I, you know I do discuss costs,
NOTE Confidence: 0.925201375
01:01:03.731 --> 01:01:05.777 you know risk benefit with patients
NOTE Confidence: 0.925201375
01:01:05.777 --> 01:01:07.740 when I talk about transplant
NOTE Confidence: 0.925201375

01:01:07.740 --> 01:01:09.920 especially in standard risk MRD
NOTE Confidence: 0.925201375

01:01:09.920 --> 01:01:12.234 negative patients as patients who
NOTE Confidence: 0.925201375

01:01:12.234 --> 01:01:14.114 are considered that presumably
NOTE Confidence: 0.925201375

01:01:14.114 --> 01:01:15.524 transplant and relying.
NOTE Confidence: 0.910012605

01:01:18.690 --> 01:01:20.194 And I'm sorry, I had difficulties
NOTE Confidence: 0.910012605

01:01:20.194 --> 01:01:21.998 with odd earlier, but I
NOTE Confidence: 0.842675274285714

01:01:22.050 --> 01:01:24.185 I do agree with what's been said.
NOTE Confidence: 0.842675274285714

01:01:24.190 --> 01:01:26.958 MRD does have a value and its primary
NOTE Confidence: 0.842675274285714

01:01:26.958 --> 01:01:28.950 significances in predicting progression
NOTE Confidence: 0.842675274285714

01:01:28.950 --> 01:01:30.690 free survival and overall survival.
NOTE Confidence: 0.842675274285714

01:01:30.690 --> 01:01:32.170 So we do use it in practice
NOTE Confidence: 0.842675274285714

01:01:32.170 --> 01:01:34.240 as a prognostic tool and with
NOTE Confidence: 0.86610916

01:01:34.250 --> 01:01:36.860 enough data with more mature data, we,
NOTE Confidence: 0.86610916

01:01:36.860 --> 01:01:40.100 we, we, we will most likely in the
NOTE Confidence: 0.86610916

01:01:40.100 --> 01:01:42.700 future use the data to discontinue
NOTE Confidence: 0.874376228333333

01:01:42.710 --> 01:01:44.858 certain patients with low risk cytogenetics

NOTE Confidence: 0.772469423333333
01:01:44.870 --> 01:01:48.278 and durable sustained MRD negative state.
NOTE Confidence: 0.831060438461539
01:01:49.570 --> 01:01:50.971 Hey, wonderful. Well,
NOTE Confidence: 0.831060438461539
01:01:50.971 --> 01:01:55.610 we are after time as it is one of three.
NOTE Confidence: 0.831060438461539
01:01:55.610 --> 01:01:59.048 So I will like to thank all of our
NOTE Confidence: 0.831060438461539
01:01:59.048 --> 01:02:01.184 panelists for their presentations and input
NOTE Confidence: 0.831060438461539
01:02:01.184 --> 01:02:04.030 today and thank you all for joining us.
NOTE Confidence: 0.831060438461539
01:02:04.030 --> 01:02:06.430 Please tune in next Friday
NOTE Confidence: 0.831060438461539
01:02:06.430 --> 01:02:09.088 for the next in the series.
NOTE Confidence: 0.831060438461539
01:02:09.090 --> 01:02:10.400 Have a good afternoon everyone.
NOTE Confidence: 0.831060438461539
01:02:10.670 --> 01:02:13.170 Thank you. 581.